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The effectiveness of digital health
technologies to support surgical patients
in changing health behaviours: a
systematic review and narrative synthesis
A. Robinson, A. Husband, B. Slight and
S. Slight
Newcastle University, Newcastle, UK
Introduction: Digital technologies (DTs) play an integral
part in everyday life. Statistics estimate 78% of adults
own a smartphone, 90% of people regularly access the
internet at home, and 20% use wearable technologies
such as fitness trackers1. This uptake has been echoed in
healthcare with successful shifts towards DT integration
to improve outcomes. DTs can aid diagnoses and
improve clinician communication and information trans-
fer across sectors2. For patients, DTs can enhance edu-
cation, improve communication with clinicians, and
empower shared decision-making and health behaviour
change (HBC).2 In surgical contexts, evidence has linked
better health behaviours and physical-preparedness prior
to surgery, with improved post-operative outcomes.2
Specifically, improvements in a patient’s weight, dietary
intake, and physical activity levels have been associated
with better tolerance of post-surgical treatment and
long-term prevention of ill health.2 At present, there are
variable amounts of support available for elective surgi-
cal patients to make these beneficial HBCs. DTs (such
as activity trackers and smartphone applications) pre-
sent an innovative opportunity to engage patients as
active partners in their care, whilst supporting HBC and
potentially optimising surgical outcomes.2
Aim: To conduct a systematic review and narrative synthesis
examining the effectiveness of DTs to support elective surgi-
cal patients in changing their health behaviours, specifically
focusing on physical activity, weight, and dietary intake.
Methods: This review was conducted according to Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines and registered with
PROSPERO: CRD42019127972. Medline, Embase,
CINAHL, PsycInfo, Web of Science, and Scopus data-
bases were searched in March 2019. Experimental
studies evaluating a DT-based intervention for surgical
patients were included, specifically focusing on three
elective specialties (bariatric, cancer, and orthopaedic
surgeries) where pharmacists can play an enhanced role
in supporting and educating patients. Emergency/acute
surgeries were excluded, and no limit on publication
dates was applied. Joanna Briggs Critical Appraisal
tools were used for quality/bias assessment.
Results: Seventeen studies from seven different countries,
published between 2011 and 2019, were included. They
focused on adult surgical patients undergoing bariatric
(59%, n = 10), cancer (29%, n = 5), and orthopaedic sur-
gery (12%, n = 2). We identified three key factors con-
tributing to DT effectiveness in supporting HBC in
elective surgical populations, specifically: intervention
delivery, implementation, and theoretical-underpinning.
e-Platforms demonstrated HBC (P ≤ 0.05) in 75% of
studies; however, this method may be superseded in the
near future with increasing prevalence of wearable tech-
nologies and apps. HBCs were found in 100% of studies
implementing DTs across the entire pre- and post-opera-
tive period, compared to 40% and 62.5% of those target-
ing only the pre-operative and post-operative periods,
respectively. Eight studies included HBC theories in their
design: 75% (n = 6) produced HBC (P ≤ 0.05) relating to
reduced weight regain, increased PA and improved diet.
Conclusion: Findings demonstrate that DTs effectively
support HBC in elective surgical patients. Study size
was a recognised limitation, where further research in
larger populations may strengthen conclusions. By
recognising factors contributing to DT effectiveness,
these findings can support recommendations for elective
surgical outcome improvement and further reiterate
HBC to improve population health.
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Introduction: Women who experience addiction, particu-
larly to drugs such as heroin, with associated poor self-
care and nutrition, can experience absence of menstrua-
tion, and temporary reduction in fertility gives rise to
belief that they will not conceive. However, when sta-
bilised on opiate substitution treatment (OST), with
associated improved lifestyle and diet, fertility often
returns. As ovulation precedes menstruation, this can be
without knowledge of potential to conceive, creating
vulnerability to unintended pregnancies. Community
pharmacists undertake most daily supervision of OST
consumption, recommended in early treatment1. This
creates an opportunity to provide reproductive health
services and advice early on when needed, taking advan-
tage of daily contact. This study was undertaken to
inform development of such an intervention.
Aim: To investigate pharmacists’ perspectives on provid-
ing reproductive health services to women receiving OST.
Methods: Semi-structured interviews using a schedule
based on COM-B and Theoretical Domains Framework
(TDF)2. Participants were recruited via head offices
(multiples) and Local Pharmaceutical Committees. Inter-
views were recorded and transcribed verbatim. Data
analysis included deductive coding using TDF, collapsed
into COM-B domains. Second stage inductive analysis
comprised re-reading and reviewing deductive codes and
identifying inductive themes.
Results: Twenty community pharmacists practising in
London and South West England participated. Five
inductive themes were identified: (1) Pharmacists’ knowl-
edge and experience of women’s RH needs. Many partici-
pants had seen their female OST patients getting
pregnant, both planned and unplanned. Most described
not having enough knowledge about the relationship
between OST and fertility. (2) The trigger, the need and
a structure: pharmacists’ style of providing services. Data
illustrate differences in automatic and reflective motiva-
tion of pharmacists, depending on whether participants
saw the service as one to provide proactively and oppor-
tunistically, or in response to a trigger. Participants
described their need for “something to hook on” e.g. the
patient initiating the subject, illustrated by participant 2:
‘a lot of the information we provide in the pharmacies is
opportunistic it would be kind of where you have a patient
asking you or it might come up- a patient not sure, or when
we do an emergency hormone contraception supply. . .”.
Confidence and beliefs about capabilities were identified
as important. Emotions of the pharmacist and stigmatisa-
tion of patients were also central influences. (3) Pharma-
cists’ perception of the relationship between them and the
women. Pharmacists believed that having a good rap-
port/relationship with women on OST was key in deter-
mining whether individuals would engage in a pharmacy-
based reproductive health intervention. (4) Social influ-
ences. Participants said they probably wouldn’t approach
the subject of reproductive health when a woman is
accompanied e.g. by children or partners. Some felt pro-
viding or advertising such services may have a negative
effect on business. (5) Privacy and funding. This com-
prised environmental factors that influenced or were
perceived to influence provision of reproductive health
advice to women on OST. Most are not unique to OST
patients, with the exception of security, safety and use of
the consultation room.
Conclusions: Community pharmacists could be well
placed to provide women receiving OST with reproduc-
tive health advice and support. The COM-B system/
TDF helped identify factors to inform design of the ser-
vice and training, including barriers to be considered.
This study is limited in that those who volunteered may
have more positive views than others.
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Introduction: Deprescribing medicines where the poten-
tial for harm outweighs the benefits is not routine practice
in hospital1. The hospital deprescribing implementation
framework provides 44 behaviour change techniques
(BCTs) to address the four barriers and one enabler
(Table 1) prioritised by geriatricians and pharmacists for
hospital deprescribing interventions2. BCTs should be
selected from the framework by the target audience to
develop an intervention according to contextual factors
and the APEASE criteria (affordability, practicability,
effectiveness, acceptability, safety and equitability).
Aim: This study aimed to support geriatricians and
pharmacists to select BCTs from the hospital deprescrib-
ing implementation framework for an intervention in
the English hospital context.
Methods: A panel of geriatricians and pharmacists was
convened to participate in a consensus study comprising
of the following two-stages: Stage 1: Initial voting round
(online survey). Stage 2: Face-to-face nominal group tech-
nique. The panel selected BCTs from the hospital depre-
scribing implementation framework according to whether
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they met the APEASE criteria for the English hospital
context in stage 1. A consensus threshold was set
of ≥ 80% agreement that a BCT met all of the APEASE
criteria and a partial consensus threshold of ≥ 80%
agreement across at least three of the criteria. Stage 2
involved the panel participating in one nominal group
technique cycle (silent generation, round robin, clarifica-
tion, voting and discussion) per BCT that achieved partial
consensus from stage 1 in order to accept or reject. The
panel was then asked to characterise all accepted BCTs
from stages 1 and 2 in terms of how they may be opera-
tionalised in the English hospital context.
Results: Four geriatricians and five pharmacists were
recruited to the expert panel representing five English
hospitals. Three BCTs achieved consensus in stage 1
and were automatically accepted for the intervention. A
further three BCTs achieved partial consensus in stage
1, of which two reached consensus at stage 2 and were
accepted for the intervention. The panel failed to reach
consensus to include a BCT to address the enabler of
‘incentivising deprescribing’. Instead, the panel proposed
addressing the enabler by “measuring, reporting and
sharing levels of deprescribing between wards or hospi-
tals”, which aligns with the BCT ‘social comparison’.
The six characterised behaviour change techniques to
address the four barriers and one enabler prioritised for
deprescribing are presented in table 1.
Conclusion: Selection of BCTs by the target audience
for intervention development is feasible. Behaviour
change interventions targeting geriatricians’ and phar-
macists’ deprescribing behaviour in the English hospital
context should include the six characterised BCTs. These
provide an evidence-base for supporting routine depre-
scribing in hospital. The dose, frequency and mode of
delivery of the BCTs will require modelling and feasibil-
ity testing prior to larger scale testing.
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Innovation in Community Pharmacy
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quantitative study
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L. Houldcroft1, B. Legay3, H. Ahmed1,
K. Hood1, R. Cannings-John1 and A. Evans4
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Introduction: The first NHS funded Sore Throat “Test
and Treat” (STTT) was introduced in selected commu-
nity pharmacies in one nation in the United Kingdom
(UK) in November 2018. Patients ≥6 years old with
acute sore throat self-presenting to a participating phar-
macy could receive a clinical examination by a pharma-
cist who had completed extra training, an immediate
Point-of-Care Test (POCT) if the threshold clinical scor-
ing criteria were met, and a supply of antibiotics under
a Patient Group Direction if the POCT was positive.
One of the main aims of the new service was to change
patient health-seeking behaviour towards visiting their
pharmacist instead of their GP, hence better utilising
pharmacist skills and freeing up GP time for more com-
plex and urgent medical issues, in line with principles of
Prudent Healthcare.
Aims: To determine patient satisfaction with the new
STTT service and explore whether it influenced patient
health-seeking behaviour.
Method: A short, self-administered patient experience sur-
vey was developed in collaboration with members of the
public, including a mix of closed and open questions. The
survey was distributed to all patients who had completed a
consultation, regardless of the outcome, between Novem-
ber 2018 and May 2019. A pre-paid envelope was supplied
for return of the completed surveys and a link to online
submission was provided. All data from completed surveys
were entered in Jisc Online Surveys and exported to
Excel for descriptive statistics. Free-text comments were
imported in Word and deductive thematic analysis was
used in relation to access and future intentions.
Results: A total of 510 completed surveys were received
by the end of the data collection period (510/2750 consul-
tations, response rate 18.5%). Of all patients, 67.3%
(n = 343) tried to see a GP before going to the pharmacy.
Deductive analysis of free-text comments revealed two
themes: convenience and accessibility, and perceived
value of the service. Patients discussed accessibility of the
pharmacist, reduced waiting times in relation to attending
a GP appointment, increased understanding of the differ-
ence between bacterial and viral infections, and how the
structure of STTT reassured them about their condition.
Overall patient satisfaction was 99.2%. A total of 98.8%
of patients (n = 504) stated that next time they had a sore
throat they would return to the pharmacy instead of
going to the GP, indicating a shift in health-seeking beha-
viour in relation sore throat symptoms.
Conclusion: A key factor in supporting the Welsh
Government to deliver their vision for “A Healthier
Wales” is to work closely with community pharmacists
and ensure that services in primary care are safely rebal-
anced to create capacity for GPs to manage more complex
conditions and patients that would otherwise would need
to be under hospital care1. This study evaluated patient
acceptability with a service that was introduced in Wales
to support transfer of uncomplicated sore throat manage-
ment to community pharmacies. Data from patient satis-
faction surveys revealed high patient acceptability of the
pilot STTT service and evidence of a shift in health-seek-
ing behaviour. These results, coupled with results from a
study exploring pharmacists’ acceptability of the service,
suggest that potential benefits include providing an alter-
native, preferred pathway for patients with sore throat2.
As the response rate was quite low, feedback obtained
may not be representative of some patient subgroups.
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A qualitative exploration of young
peoples’, pharmacists’ and contract
managers’ perceptions of the
community pharmacy chlamydia
screening service
L. Ahmaro1, L. Lindsey1, S. Forrest2 and
C. Whittlesea3
1Newcastle University, Newcastle, UK 2Durham University, Durham, UK
and 3University College London, London, UK
Introduction: Chlamydia is the most common sexually
transmitted infection in the UK particularly among young
people. If not treated, it increases the risk of transmission
and serious health consequences including infertility in
both sexes. To reduce these risks, many community
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pharmacies provide free chlamydia screening for young
people. In 2018, screening activity among this age group
was lower than previous years, and less than 1% were
screened in pharmacies compared to other settings1. The
reasons why uptake is low in pharmacies are unclear.
Aim: To investigate why community pharmacy screen-
ing activity is low, this study aims to understand the fac-
tors that influence uptake of screening by exploring the
views of young people, pharmacists, and sexual health
contract managers.
Methods: Semi-structured interviews were conducted
with young people including service users, pharmacists,
and contract managers who assign the service to pharma-
cies. Information leaflets were provided to 40 youth club
members aged 16–24. Participants were then recruited
using quota sampling (see Table 1) and interviewed at the
clubs. The topic guide covered knowledge of chlamydia
and associated risks and thoughts about the pharmacy
screening method. Using thematic analysis, audio-
recorded responses were transcribed and coded in NVivo
Ver11 to produce themes, then re-coded under constructs
of the Health Belief Model and findings compared.
Table 1. The sample variables for interviewing young
people.
Sample size: n = 30
Ages: 16–24
Sample variables At least 20% of men and 20%
of women have been
previously tested for an STI
At least 20% of men and 20%
of women have used a
pharmacy sexual health
service including chlamydia
testing
At least two participants
representing each age from
16–24 interviewed
There were 102 pharmacists and 2 contract managers
invited to take part in the study by post. Stratified sam-
pling was used to recruit the participants who were then
interviewed at work or over-the-telephone depending on
preference. The topic guide for both participant groups
broadly covered constructs of the Normalization Process
Theory Model2 to identify the factors required for inte-
gration of the screening service into routine work.
Results: Interviews were conducted with 25 young people,
22 pharmacists and 2 contract managers as key infor-
mants. Among young people, concerns regarding privacy
and feeling judged when requesting a chlamydia kit were
perceived barriers ‘Don’t make it feel like there’s a mas-
sive elephant in the room.’ Pharmacists suggested further
training needs to deliver a more young people-friendly
service to maximise cognitive participation ‘Training is a
bit more. . .required on how to talk to youngsters. . . they
sometimes don’t know how to talk to somebody about
what’s happened to them’. All three participant groups
believed that the accessible location and opening hours of
pharmacies made them ideal for screening, but that the
service required greater promotion.
Conclusion: This is the first study to explore the percep-
tions of all three stakeholders on the pharmacy chlamy-
dia screening service. However, the views of pharmacy
support staff about screening were not explored due to
time limitation. Findings and proposed recommenda-
tions will be disseminated to local decision-makers and
pharmacy committees to inform practice. Future work
will involve designing a framework with policy makers
to maximise service delivery.
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GP2Pharmacy: a quantitative evaluation
of a novel locally commissioned
community pharmacy referral service in
South Tyneside
A. Moore, M. Conway, A. Sturrock and
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Introduction: General practice is seeing increased demand
for rapid access appointments and higher patient expecta-
tions. The NHS Long Term Plan suggests a need to better
utilise the skills, experience and knowledge of community
pharmacists in order to relieve some of the pressure on
prescribers in primary care.1 GP2Pharmacy is an innova-
tive service, which utilises PGDs (including antibiotics for
urinary tract infections and tonsillitis) alongside an exist-
ing minor ailments scheme. Additional clinical skills
training was provided for pharmacists providing the ser-
vice. There were 8000 appointments available in the initial
pilot. Patients contact their practice as normal where
reception staff can book fixed time appointments for suit-
able patients with their local pharmacist.
Aim: To evaluate the GP2Pharmacy service via analysis
of quantitative consultation data, specifically in refer-
ence to the provision of prescription only medicines via
PGDs and patient feedback questionnaire responses.
Methods: All GP2Pharmacy consultations are recorded
on PharmOutcomes and South Tyneside CCG provided
access to anonymised consultation and patient feedback
questionnaire data at 3 months and 6 months into the
pilot. Data were statistically analysed using SPSS V25;
particular attention was given to variables (including
patient age, referring surgery and presenting complaint)
affecting the outcome and evaluation of the
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consultation, using chi-squared tests. Any questionnaire
free text comments were qualitatively explored for
insight.
Results: In the first six months of the service, 741 patients
were referred to one of the community pharmacies
enrolled in the service (n = 24) to provide advice (15%),
treatment with an over-the-counter product (47%) or
same day referral back to the GP (14%). Six patients were
referred to urgent care. A PGD medication was provided
in 21% of consultations, including 79 patients for nitrofu-
rantoin, 37 patients for fusidic acid and ten patients for
phenoxymethylpenicillin.. Of patients accessing the ser-
vice, 24% were under 13 and 12% were over 65 years of
age. Reception staff referred 96% of patients.
Further analysis highlighted that the range of pre-
senting complaints did not fully utilise the wide range of
PGDs available under the service, for example, aciclovir
for shingles. Furthermore, over half of all PGD referrals
came from just two surgeries out of 14 registered for the
service (P ≤ 0.001, Cramer’s V = 0.243).
The feedback from patients highlighted the benefits
of increased and quicker access to a healthcare profes-
sional. Negative comments included booking an
appointment and locum pharmacists not having an ade-
quate understanding of the service.
Conclusion: While this analysis highlights the potential
viability of extended minor ailment schemes, with many
patients highlighting the benefits of easier access to
required medications through their community pharma-
cist, there was an underuse of available appointments and
specifically those that require provision of prescription
only medications via a PGD. The quantitative approach
utilised within this research meant some emerging themes
could not be explored fully. A qualitative strand is cur-
rently underway to further explore facilitators and barri-
ers to the service with key stakeholders.
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Opioid Use
Examining trends in opioid prescribing
burden using an oral morphine
equivalence measure in a primary care
population: a retrospective, cross-
sectional study of primary care
prescribing data
E. Davies, C. Phillips, B. Sewell, M. Jones and
J. Rance
Swansea University, Swansea, UK
Introduction: Opioid prescribing has risen considerably
in the UK over the last 20 years 1 and with it, comes
increased risks to population health2. Opioid dose is an
indicator of potential harm, but understanding the bur-
den of different opioid medicines can be hampered by
the numerous doses, strengths and products available.
Aims: The study aimed to describe trends in prescribing
of opioid analgesics for non-cancer pain across Wales
between 2005–2015, using an oral morphine equivalent
dose (OMED) measure to compare dose burden between
drugs.
Methods: The Secure Anonymised Information Linkage
databank (SAIL) was searched using validated NHS
read-codes to identify prescriptions for oral and trans-
dermal opioid medicines issued in Primary Care Prac-
tices in Wales between 2005–2015. A proxy-measure for
OMED was developed, due to the lack of data for pre-
scription directions and quantity normally required to
calculate OMED. The devised measure allocated OMED
based on the strength of each product prescribed. The
OMED was multiplied by the recommended daily dose
(Medicines.org) and the number of prescriptions issued
each year to determine annual totals for each drug.
Data were measured in repeated, annual cross-sections
and adjusted for population. Statistical analysis used
Kruskal-Wallis H tests, as data were not normally dis-
tributed.
Results: Just over 23.5million prescriptions from 345 Pri-
mary Care General Practices were included in the analy-
sis. Total annual OMED doubled from 37,662,65 mg to
76,428,768 mg in the 11 years examined.
Overall, 71% of the opioid burden between 2005–2015
was due to 3 drugs; codeine (35%), tramadol (22%) and
morphine (14%). There was a statistically significant dif-
ference (P < 0.001, H = 73.5, ฦ2=0.8) between the groups
of drugs examined. Large increases in OMED were noted
for morphine (Table 1) in particular.
Table 1. Daily oral morphine equivalent dose (mil-
ligrams) issued on prescription, given as annual totals
and adjusted to population, stratified by drug
Year
Total daily oral morphine equivalent dose
(mg) prescribed
Codeine Morphine Tramadol
Total all
opioids
2005 13743115 3293220 7865695 37662651
2015 25593382 17047800 14252335 76428768
Percentage change
(%)
2005–2015
86.2 417.7 81.2 102.9
Total daily oral morphine equivalent dose
(mg) per 1000 population
2005 5916 1422 3397 16266
2015 10581 7063 5905 31665
Rate change (%)
2005–2015
78.8 396.6 73.8 94.7
Oral morphine equivalent dose per
prescription issued (mg)
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Table 1. (Continued)
Year
Total daily oral morphine equivalent dose
(mg) prescribed
Codeine Morphine Tramadol
Total all
opioids
2005 17 86 36 23
2015 19 68 38 32
Percentage change
(%)
2005–2015
16.2 20.6 5.7 35.5
Conclusion: Large increases in OMED burden were
observed over the 11 years studied. The patterns in pre-
scribing, in particular the drugs responsible for the main
burden are different to those described in England.1
Although the proxy OMED measure is an estimate, the
trends described are an accurate reflection of prescribing
in Wales and give a new insight into the burden on the
population. Future work is needed to better understand
the reasons for such large increases in opioid prescribing
and the differences between Wales and the rest of the
United Kingdom.
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Community pharmacists’ role in
preventing Opioid Substitution Therapy-
related deaths: a national survey of
English community pharmacists
R. Yadav1, J. Scott1, P. Rogers1 and
D. Taylor2
1University of Bath, Bath, UK and 2Victoria University Wellington,
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Introduction: Community pharmacists (CP) dispense the
majority of Opioid Substitution Therapy (OST) pre-
scriptions in England, and also provide related services,
such as Supervised Consumption (SC), Needle & Syr-
inge Programmes (NSP) and Take Home Naloxone
(THN). Opioid overdose deaths have increased dramati-
cally in many high-income countries in recent years.
Many of these deaths include those who inject illicit
drugs, so may access NSP and people currently or
recently in treatment for their addiction. Evidences sug-
gest OST reduces both overdose and overall mortality
but more needs to be done to prevent these deaths. UK
guidance describes pharmacy practice to reduce over-
dose but the extent to which such guidance is imple-
mented is questionable1.
Aim: To describe CPs’ self-reported adherence to guide-
lines for preventing overdose deaths.
Methods: A cross-sectional quantitative telephone sur-
vey was undertaken with CPs in England. A random
stratified sampling technique was adapted to get repre-
sentative sample from 6% of registered pharmacy pre-
mises. Information was sent to the participants in
advance by post and verbal consent was taken before
the survey was administered by phone. The question-
naire was developed based on published literature and
was piloted before use. Eligibility criteria were set as
those who provided any OST service. The survey was
administered between January and May 2019. SPSS 25
software was used for data management and analysis.
Data were subjected to descriptive analysis1.
Results: A total of 253/750 responses (34%) were
received of which 56% (n = 142) were male. Based on
the eligibility, where known, the response rate was
39% (n = 253/657). Over three-quarter (77%, n = 194)
received formal training to deliver OST services how-
ever only 40% (n = 102) were asked to provide any
evidence of training. The provision of NSP (18%,
n = 45) and THN (1.6%, n = 4) services were poor. A
significant proportion (21%, n = 54) reported to never
counsel patients about overdose risks. Only half (50%,
n = 126) counselled at the initiation stage and a third
(32%, n = 81) did so when there was a change in
dose/circumstances. The majority (63%, n = 160) did
not ensure patients have access to naloxone to treat
accidental opioid overdose. While all pharmacists
(100%, n = 253) checked prescriptions for legal cor-
rectness; one-fifth (19%, n = 48) did not always estab-
lish its clinical appropriateness. Almost all CPs
consulted the prescriber (97%, n = 245) when three or
more consecutive doses have been missed but only
two-thirds (62%, n = 157) withheld dose from intoxi-
cated patients.
Conclusion: Guidance which is pertinent to legal
aspects (e.g. prescription legality) is more closely
adhered to than those requiring knowledge and profes-
sional judgement (e.g. clinical assessment, withholding
dose). OST patients are more likely to suffer overdose
fatality during initiation and abstinence stage, the lack
of overdose counselling in these critical stages, there-
fore, is an area of immediate concern. The ‘mechanics
of delivering the service’ forms the central premise of
the current practice and the notion of ‘preventing over-
dose death’ is peripheral. Pharmacists’ education on
overdose prevention, their motivation to intervene in
risk situations, improving access to NSP and THN in
pharmacies all needs attention. Nonparticipation of
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two large multiple chains in the survey is one of the
limitations of this research.
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A theory and evidence-based health
service model for tapering opioids in
chronic non-cancer pain: a realist review
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Introduction: Numerous interventions have been devel-
oped to address opioid overuse for chronic non-cancer
pain. A 2017 systematic review identified several effec-
tive interventions for tapering long-term opioids yet lim-
ited progress has been made with successfully
integrating these into routine healthcare practice1. This
lack of adoption may be due to limited understanding
of the barriers and enablers to practitioners delivering
these interventions in the real-world environment. Real-
ist methodology combines theory with research and
practice evidence to understand the mechanisms by
which intervention components exert their effect. This
understanding enables effective components to be trans-
lated from the trial to the real-world environment whilst
maintaining efficacy.
Aim: To understand from the practitioner perspective,
what elements of opioid tapering interventions work.
Methods: The theoretical domains framework under-
pinned the realist review; it comprises 14 domains each
representing barriers and enablers to practitioners
implementing a behaviour. For each domain, we for-
mulated programme theories regarding the require-
ments for a healthcare professional to effectively taper
opioids. We refined these through discussion with a
stakeholder panel of eight primary and secondary care
pharmacists and doctors. We identified relevant pub-
lished literature from the 2017 systematic review of
interventions for tapering long-term opioid therapy1.
We combined these data with a semi-structured survey
of stakeholders involved in intervention implementation
in England. We tested the resulting programme theo-
ries with the published literature and survey data. We
iteratively refined the programme theories to include
only those supported by the evidence and combined
this final set of theories into one (mid-range theory)
which was presented to the stakeholder panel for any
further refinement.
Results: From 56 published and 16 implemented inter-
ventions representing primary care, hospital, specialist
pain facilities and the prison service, doctors were most
frequently involved in delivering opioid tapering inter-
ventions whilst pharmacists were often the drivers of
establishing tapering interventions. Of the nine pro-
gramme theories generated after initial stakeholder panel
refinement, seven were supported by the evidence to
generate the final mid-range theory. The overarching
enabler to practitioners engaging with an opioid taper-
ing programme is presence of a clear expectation that
opioid tapering is their responsibility. This may be
achieved in a variety of ways including incentivisation.
Practitioners are further enabled by programmes incor-
porating information about the consequences of excess
opioid use and guidelines on how to taper; these were
often prepared by pharmacists. Programmes should fur-
ther enable practitioners by equipping them with appro-
priate knowledge and skills to initiate tapering
discussions and navigate the patient pathway. All mem-
bers of the healthcare system should adopt a consistent
approach to opioid tapering. Providing access for
patients to comprehensive education, appropriate levels
of psychological and physical support addresses patient-
related barriers to tapering.
Conclusions: Inferences are limited by the survey data
being derived only from one country, however, through
combining with the peer-reviewed literature representing
numerous countries, we have greater confidence in the
likely transferability of findings. Healthcare organisa-
tions commissioning opioid tapering programmes should
therefore ensure that all components of the mid-range
theory are addressed. Characterisation of each compo-
nent should be determined by individual health systems
according to existing structures and resources.
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Polypharmacy
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A. Gorman1, A. Rankin2, H. Barry2,
C. Cadogan3, G. Gormley4, T. Fahey5,
C. Ryan1, E. Gardner6, A. Agus6,
C. Leathem7, M. Maxwell7, G. Molloy8,
A. Ferrett9, P. McCarthy10 and C. Hughes2
1School of Pharmacy and Pharmaceutical Sciences, Trinity College
Dublin, Dublin, Ireland 2School of Pharmacy, Queen’s University Belfast,
Belfast, UK 3School of Pharmacy and Biomolecular Sciences, Royal
College of Surgeons in Ireland, Dublin, Ireland 4School of Medicine,
Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast,
UK 5Department of General Practice, Royal College of Surgeons in
Ireland, Dublin, Ireland 6Northern Ireland Clinical Trials Unit, Belfast, UK
7Northern Ireland Clinical Research Network Primary Care, Belfast, UK
8School of Psychology, National University of Ireland, Galway, Galway,
Ireland 9Public Involvement Enhancing Research Northern Ireland,
Belfast, UK and 10Donegal Volunteer Centre, Donegal, Ireland
Introduction: Polypharmacy is considered ‘one of the
most pressing prescribing challenges’1 and is often
viewed negatively. Appropriate polypharmacy acknowl-
edges multiple medications may be required for older
people (≥65 years) with multimorbidity, emphasises the
need to ensure that prescribing is evidence-based and
potential drug interactions are avoided. Members of
the research team have previously developed an inter-
vention to improve appropriate polypharmacy, using
the Theoretical Domains Framework (TDF). The inter-
vention includes a video demonstrating how to pro-
mote appropriate polypharmacy during a typical
general practitioner (GP) consultation with an older
patient and a patient recall process. Preliminary testing
was completed in two general practices in Northern
Ireland (NI)2. The next stage of the research will test
the intervention in a larger pilot cluster randomised
controlled trial (cRCT) across NI and the Republic of
Ireland (ROI).
Aim: To refine the existing intervention prior to imple-
mentation in a pilot cRCT in both jurisdictions to
account for possible differences in context and practice
in ROI.
Methods: A purposive sample of 12 general practices in
the six border counties of ROI (Cavan, Donegal, Lei-
trim, Louth, Monaghan, Sligo) were recruited. Semi-
structured interviews were conducted with recruited GPs
who were asked for their views on the intervention.
Questions related to the video content, recall process,
mode of delivery, and required changes for the ROI
context. Interviews were audio-recorded and transcribed
verbatim; an in-depth familiarisation process was under-
taken (repeated reading and listening to interviews).
Transcripts were analysed by content analysis using a
framework approach to identify key themes. The emer-
gent coding scheme was reviewed, agreed and the main
themes were developed into a framework matrix.
Results: Interviews were conducted with 13 GPs in 12
practices, across five counties. Key themes identified
were: clinical scenario used in the video, engagement
with and length of video, potential enablers and barri-
ers to intervention implementation. GPs were positive
about the intervention and thought it ‘would probably
fit into most practices’ and that the video ‘was concise
and useful’. Some concerns were noted about time con-
straints (‘obviously if you had more time, we would be
much more thorough about things’) and a lack of
resources (‘at this moment in time the resources are dif-
ficult’). Minor suggestions to the video component
included ‘some up to date medical evidence-based medi-
cine’ and ‘tools you can use to perform medication
reviews’. GPs suggested small additions to the interven-
tion, including a staff information sheet and a patient
recruitment poster.
Conclusions: Using a theoretical basis for development,
this study follows recommendations by the Medical
Research Council in the development of complex inter-
ventions, enhancing the rigour of the study. However,
not all counties were represented and the views
expressed are not generalisable. However, findings from
this study have enabled refinements to be made to an
existing intervention to account for contextual differ-
ences between ROI and NI practices. The refined inter-
vention package will be used in the larger cross-border
pilot cRCT.
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Exploring the nursing practice
surrounding co-administration of
multiple medicines in intensive care
units
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Introduction: Intensive care unit (ICU) patients are usu-
ally prescribed multiple intravenous infusions, which
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sometimes exceed the number of available venous access
sites. To ensure administration, medicines can be co-
administered through the same lumen of a venous cathe-
ter using a Y-site connector. This increases the chances
of combining incompatible medicines that can present in
the form of precipitates and lead to catheter occlusion
and occurrence of potentially fatal venous embolism
which can compromise patient care1. Therefore, it is
important that compatibility is assessed prior to co-
administration.
Aim: To explore the practice of medicine co-administra-
tion and how medicine compatibility is assessed amongst
ICU nurses.
Methods: A cross-sectional survey was conducted
among ICU nurses across 22 hospitals in England
between February 2019 and August 2019 through the
use of an online questionnaire. The questionnaire was
developed to investigate the process of co-administra-
tion, how compatibility is assessed in practice and how
nurses manage co-administration challenges. Using eight
ICU nurses across two hospitals, the questionnaire was
validated using content validity. The final questionnaire
consisted of 23 items (open and closed questions) and
was distributed via email. Data were analysed using
descriptive statistics.
Results: An estimate of 899 nurses received the ques-
tionnaire, and a total of 297 nurses responded (esti-
mated response rate of 33%). The average content
validity for the questionnaire had value of 0.82 revealing
a high level of agreement. The majority (84.2%;
n = 277) of the nurses worked in adult ICUs with
44.8% having over 10 years’ professional experience in
ICUs. Most nurses (94%; n = 278) combine medicines
down the same lumen and 70.9% (n = 197) use a Y-site
connector to facilitate co-administration. Of those who
use a Y-site connector, 81.7% (n = 161) reported co-
administering two medicine combinations, 26.9%
(n = 53) three combinations and 7.6% (n = 15) four
combinations. Before co-administering medicines, 99.3%
(n = 276) of nurses checked for medicine compatibility.
The resources used to check compatibility include cross
table compatibility charts, experience, drug monographs,
Trissel’s Handbook of Injectable Drugs, MEDUSA –
injectable medicines guide, pharmacists, colleagues and
the British National Formulary (BNF). However, 69.4%
(n = 206) of nurses felt that these resources have limited
compatibility information for commonly used medicines
in ICU, with the compatibility chart ranking as the most
preferred resource (66.7%, n = 198) because it was quick
to use. Trissel’s was least used with some nurses never
having heard of it. In the absence of compatibility data,
co-administration was avoided by 69.9% (n = 206) of
nurses. However, to ensure that patients still received
their medication most nurses either prioritised infusions
or requested additional venous access.
Conclusions: A limitation of this study is that we did
not obtain an even distribution of responses across Eng-
land meaning that findings are not as generalisable. The
use of a national questionnaire has helped identify that
co-administration of medicines is common practice and
that there is a need for compatibility data that is rele-
vant to current clinical practice. Since nurses prefer to
use a quick reference compatibility guide, organisations
should direct more attention towards updating such
resources on a regular basis to reflect medicine use
within ICUs.
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An exploration of the ‘medicines work’
of people living with complex
polypharmacy regimes in very remote
and rural Scotland: keeping the patient
at the centre
A. Grant1, K. MacLure1, K. Gallacher2,
T. Dreischulte3, A. Mair4 and D. Stewart5
1Robert Gordon University, Aberdeen, UK 2University of Glasgow,
Glasgow, UK 3University of Dundee, Dundee, UK 4Scottish,
Government, UK and 5University of Qatar, Doha, Qatar
Introduction: With an aging population there are
increasing numbers of people who are self-managing
multiple morbidities, their healthcare and often complex
medication regimes (polypharmacy). The more condi-
tions a person has the more medications they are likely
to be prescribed. Medications can interact creating side-
effects and more medications are then prescribed for
those interactions resulting in increased ‘medicines
work’1. The risk of medication-related problems
increases with each drug prescribed and those with more
conditions may experience more treatment burden and
lower quality of life. People with multiple morbidities
receiving complex polypharmacy regimes (10 + medici-
nes) are often elderly and frail.
Yet the work for patients in self-managing their
complex polypharmacy has yet to receive sociological
attention. The ‘medicines work’ of self-managing com-
plex polypharmacy is needed to better understand
how the burden impacts on patients’ everyday life,
their agency and capacity to self-manage, the
resources and support networks they utilise, strategies
for (un)intentional non-adherence and (non-) compli-
ance1. Novelty and inclusivity are added to the
research by seeking the voices and experience of very
remote and rural patients resident on Scotland’s smal-
ler islands.
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Aim: The aim of this study was to explore the experi-
ences of very remote and rural patients polypharmacy
regimes in self-managing their ‘medicines work’ using
Burden of Treatment theory.
Methods: Qualitative research using self-reporting longi-
tudinal diaries with follow-up in-depth face-to-face
interviews2 was conducted with patients resident in out-
lying islands of Orkney. Fully informed consent was
gained with permission to audio-record interviews. Dia-
ries and interviews were based on Burden of Treatment
Theory (BTT) which focuses on Capacity (Agency, Rela-
tionality, Control, Opportunities); Expressing capacity
(Functional performance, Social skill, Social capital,
Structural resilience); Patient work (Sensemaking, Cog-
nitive participation, Collective action, Reflexive monitor-
ing). The diaries, issued in advance, were designed to
capture patients’ prescribed medications, daily regime,
(non-)adherence and (non-)compliance, support with
medications and daily ‘medicines work’ over one week.
The semi-structured interviews explored in more depth
factors which impact their medication regime, access to
healthcare and quality of life including ‘medicines
work’.
Results: NHS Orkney staff screened GP-held patient
records to identify island residents on 10 + medications.
Of the 12 patients identified, 11 consented to take part
and were mailed longitudinal diaries. These were com-
pleted by most patient participants (n = 9). Two cited
difficulty in writing up their diaries due to a stroke
(n = 1) or rheumatoid arthritis (n = 1). Challenges of
data collection were experienced as participants were
resident on the islands of Hoy (n = 8) and Westray
(n = 4). Most were male (n = 8); ages ranged 54 to
81 years. Remote island living was not viewed as a dis-
advantage as patients spoke positively of their health-
care experience (access to GP, Nurse Practitioner, repeat
medications) and quality of life despite the ‘medicines
work’.
Discussion: Early analysis of the data collected from this
small sample reflects the qualitative themes of the coun-
ter the expected ‘medicines work’ load and age of
patients managing polypharmacy in very remote and
rural Scotland. Further analysis and comparison with
the literature are underway.
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Influences on Prescribing
The relationship between first-line
therapy in Parkinson’s disease patients
and social deprivation status, does a
delay in PD diagnosis mediate this
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Introduction: Some UK studies have found a signifi-
cantly lower incidence of Parkinson’s disease (PD) in
the most socially deprived areas1. This led to the
hypothesis that those who reside in socially deprived
areas may be more likely to experience delays in a PD
diagnosis1. Levodopa is the mainstay therapy in manag-
ing PD motor symptoms. However, due to the motor
side effects, including levodopa-induced dyskinesia,
some clinicians delay levodopa treatment and initiate
levodopa sparing strategies such as monoamine oxidase
B (MAO-B) inhibitors2 that do not display such side
effects.
Aim: To examine the effect of social deprivation on PD
incidence rates and to identify any differences in pre-
scribing decision making with respect to initiating levo-
dopa therapy vs MAO-B inhibitors in areas of different
social deprivation. Our hypothesis is that if a higher
social deprivation status is associated with a lower PD
incidence rate, and also associated with a high rate of
initiating levodopa as first-line therapy, this could be
because patients who live in areas with higher levels of
social deprivation are more likely to experience delayed
PD diagnosis.
Methods: We conducted a population-based study of res-
idents in Wales, UK, aged 40 years or older and newly
treated with PD medications between 2000 and 2016,
using the Secure Anonymised Information Linkage
(SAIL) Databank. Patient characteristics, comorbidities,
and first-line therapy were extracted. The social depriva-
tion status was classified according to the Welsh Index of
Multiple Deprivation (WIMD) 2011 scale (quintile 1 –
most deprived, up to quintile 5 – least deprived). The
annual incidence of PD was estimated using the Read
codes for PD diagnosis. Poisson regression was used to
estimate the incidence rate ratio (IRR) across the study
period. A series of logistic regressions were run to deter-
mine the effect of WIMD quintile on first-line therapy
choice. Other variables including sex, comorbidities, and
previous medications history were controlled for.
Results: After analysing 16,693,205 single person-years
during 2000–2016, the incidence rate of PD was
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significantly lower in the most deprived quintile com-
pared to the least deprived quintile (IRR = 0.82, 95%
CI 0.77–0.87). Patients who lived in the least deprived
quintile area were 22.1% less likely to be prescribed
levodopa compared to patients from the most deprived
quintile area (P-value = 0.007). Conversely, patients
who lived in the least deprived quintile area were 98.8%
more likely to be prescribed MAO-B inhibitors
(P < 0.0001).
Conclusions: Given that MAO-B inhibitors are often
used as initial therapy to spare patients from the motor
side effects of levodopa, individuals with lower socioeco-
nomic status may be diagnosed later in their disease, in
which case the prescriber may commence treatment with
levodopa as the disease has progressed. This interpreta-
tion is reinforced by the fact that the incidence of PD
was significantly lower in the most deprived areas, which
may be due to delayed diagnosis. Given their accessibil-
ity, pharmacists could play a role in identifying early
signs and symptoms of PD in socioeconomically
deprived area. Further research exploring this unwar-
ranted variation in care and how it may be addressed is
needed.
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What influences the uptake of
prescribing guidelines in UK general
practice? A qualitative study
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Introduction: Despite the increasing medicines’ budget and
widespread availability of evidence-based guidelines to
inform the rational use of medicines, considerable varia-
tion exists in guideline uptake and application by clinicians
1. The range of health professionals who prescribe in gen-
eral practice may contribute to this variation. Recent NHS
policy supports pharmacists’ inclusion in general practice
teams. Pharmacists’ professional skills are viewed by some
as suited to fostering an evidence-based and patient-
centred approach to prescribing 2. To develop strategies
which reduce variation and promote evidence-based pre-
scribing, there is firstly a need to identify the key determi-
nants of current prescribing behaviour.
Aim: This study investigated influences on prescribing
in general practice. The objectives were to: (1) Explore
determinants of prescribing behaviour from pre-
scribers’ perspectives. (2) Explore the use/influence of
National Institute of Health and Care Excellence
(NICE) and other guidelines on prescribing. (3)
Explore the role and potential of general practice-
based pharmacists (PBPs) to promote evidence-based
prescribing.
Methods: Semi-structured qualitative telephone inter-
views and focus groups were conducted with: (i) gen-
eral practice-based prescribers: General Practitioners
(GPs), nurses and PBPs (ii) key informants: individu-
als working in national, regional and local roles, with
responsibility for influencing, measuring and monitor-
ing general practice prescribing. A target sample
matrix was developed to reflect a range of partici-
pants, including prescribers from various professional
backgrounds and diverse general practice characteris-
tics, and key informants working in assorted NHS
roles. Recruitment was through local and regional
contacts and snowball sampling. Interviews and focus
groups were audio-recorded and transcribed verbatim.
Data collection took place between November 2018
and April 2019. Data saturation was considered to be
achieved when the sample matrix was complete and
no new themes were identified. Thematic data analysis
was used to identify themes about the influences on
prescribing and the PBP’s role.
Results: Interviews were completed with 17 prescribers
(GPs (n = 6), pharmacists (n = 6), nurses (n = 5)) and
six key informants. One focus group was conducted
with five key informants. Although prescribers and key
informants stated that guidelines fundamentally influ-
ence prescribing, they also identified competing influ-
ences including the prescriber’s professional background
and experience, demographic profiles of patient popula-
tions and attitudes of individual patients. Media por-
trayals of medicines and public opinion were identified
as substantial influences. Prescribers identified practice-
level influences, e.g. attitudes towards shared learning.
Key informants emphasised the impact of NHS organi-
sational policies and availability of services on prescrib-
ing practice. These individuals also highlighted
underlying problems (e.g. polypharmacy) as well as
‘medicines optimisation’ principles (e.g. safe prescribing)
developed to address these issues. Both samples identi-
fied the contribution made by PBPs to medicines exper-
tise and knowledge and mentioned variation in PBPs’
practice roles. Prescribers’ views were mixed about how
much PBPs’ may influence prescribing in the future.
Key informants were concerned about support and
career progression for PBPs.
Conclusions: Prescribing in the general practices repre-
sented in this study (mostly larger, with lower depriva-
tion levels) is influenced by factors which compete
with guidelines. This qualitative research study did not
quantify the relative importance of these factors.
Strategies to promote evidence-based prescribing
should reflect these influences on prescribers in varied
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practice settings and take account of the expanding
range of professionals with prescribing roles in general
practice.
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Introduction: The National Institute for Health and
Care Excellence (NICE) recommended direct oral anti-
coagulants (DOACs) for a variety of indications as
equal alternatives to warfarin, and stated that the
patient’s values and preferences should be used to guide
choice of agent in a shared decision making process1.
However, uptake of DOACs had been patchy and slow
across the UK2. Identifying the perceived barriers to
using DOACs could help to develop strategies to over-
come these and enable their use where appropriate.
Aim: The study aimed to investigate the attitudes and
perceptions of professionals towards oral anticoagula-
tion, and the choice between warfarin and the DOACs.
Methods: One-to-one semi-structured interviews were
conducted between May and July 2018. Participants
were recruited using snowball and convenience sampling,
across four NHS trusts and one Clinical Commissioning
Group. Inclusion criteria were that participants should
be either a hospital pharmacist, general practitioner, or
cardiology or care of the elderly registrar or consultant,
and involved in the initiation of oral anticoagulation. A
topic guide was used to aid the interview process; this
included questions regarding the participant’s role in pre-
scribing anticoagulation, how they felt about the choices
of oral anticoagulants, how they discussed this with
patients, any concerns they had regarding DOACs, and
if and how they used any materials to aid in shared deci-
sion making. Interviews were transcribed verbatim and
analysed using framework analysis.
Results: Thirteen interviews were carried out, lasting
between 17 and 48 minutes, with an average length of
32 minutes. Table 1 shows participant characteristics.
Current practice was found to be moving through a per-
iod of change, with a shift towards preference for
DOACs, especially for patients with non-valvular atrial
fibrillation (AF). The main themes identified were (1) an
overarching theme of change, (2) barriers and facilita-
tors to appropriate use of oral anticoagulants, (3) pro-
fessional-related factors affecting drug choice and (4)
perceptions of the shared decision making process.
Many professionals have a preferred DOAC which they
use, but the reasons for preference vary. Perceived
advantages of DOACs included a beneficial overall clini-
cal effect in treating certain indications from evolving
trial data, convenience due to reduced monitoring, and
ability to use certain DOACs in compliance aids. Tools
to aid the shared decision making process were not
widely used, and there was a perception that shared
decision making was not comprehensively approached.
Table 1. Participant characteristics
Role and specialty Number of participants
Consultant – cardiology 1 male, 1 female
Registrar – cardiology 1 male, 1 female
Consultant – stroke 1 male, 1 female
Consultant – care of the elderly 1 male, 1 female
GP 1 male
Hospital pharmacist 3 male, 1 female
Conclusions: The landscape with regards to oral antico-
agulation options was found to be in a period of
change, and there appeared to be a move towards a
preference for DOACs over warfarin. As the prescribing
of oral anticoagulants is changing towards greater num-
bers of patients prescribed DOACs, there is a need to
review the provision of anticoagulation services. One
limitation in this study is that most participants were
professionals from secondary care, with only one partici-
pant in primary care. Another limitation is that partici-
pants tended to mainly prescribe anticoagulation for
AF, however attitudes and perceptions towards use of
DOACs in other indications may differ.
References
1. National Institute for Health and Care Excellence.
Anticoagulants, including non-vitamin K antagonist
oral anticoagulants (NOACs). Key therapeutic topic
[KTT16]. 2016. Available at: https://www.nice.org.
uk/advice/ktt16 [accessed 27/08/2019]
2. Association of the British Pharmaceutical Industry
Stroke in Atrial Fibrillation Initiative. NOACs:
Innovation in anticoagulation – Optimising the pre-
vention of AF-related stroke. 2014. Available at:
http://www.abpi.org.uk/publications/noacs-innovation-
in-anticoagulation/ [accessed 27/08/2019]
16 International Journal of Pharmacy Practice 2020; Supplement S1
ªThe Authors. IJPP ª 2020 Royal Pharmaceutical Society International Journal of Pharmacy Practice, 28 (Suppl. S1), pp. 4–43
Older People
The design of patient centric drug
products to improve adherence and
acceptance in older people – a
qualitative interview study
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Introduction: Elderly patients represent a very heteroge-
neous patient population and are the major user group
of multiple prescribed medicines. Age-related changes
mean that this population can encounter barriers
towards taking medicines orally. Taking into account
these changes during drug development can lead to a
patient centric drug product that provides patients with
the best overall benefit to risk profile1. Further work is
needed to identify how the physical characteristics of
drug products can be optimised to ensure optimum
patient adherence and acceptance.
Aim: To understand the key issues faced by older peo-
ple and family/informal carers when using/administering
oral solid dosage forms from the perspectives of all
those involved in an individual’s therapy.
Methods: Purposeful sampling was used to identify
older people (aged 65 or above taking at least one oral
solid dosage form), their informal carers and health/so-
cial care professionals with experience of working with
older people. Older people and their carers unable to
speak English or lacking capacity to consent were
excluded. The study was advertised on recruitment web-
sites (including Join Dementia Research and People in
Research), within care homes, and also via NHS organi-
sations (including NHS Dudley CCG, University Hospi-
tals of North Midlands NHS Trust and NHS Southern
Derbyshire CCG). The study made use of placebo
tablets to provide participants with a point of reference
to help communicate their ideas. Interviews were audio
recorded and transcribed verbatim. Thematic analysis
was used to analyse the data2.
Results: A total of 52 interviews were conducted: 18
older people, 7 informal carers and 27 health/social care
professionals. All interviews were analysed together in
order to examine the relationship between different par-
ticipant groups. Key themes included: the impact of for-
mulation characteristics on the medication-taking
process; the current role of health/social care profession-
als when providing patient centric products and how
this role can be improved. Formulation characteristics
had a significant impact on medication identification,
handling, swallowability and overall adherence. 6 mm
round tablets were more difficult to swallow and
challenging to handle; “These are the Codeine Phos, and
I shoot those all over.” Limited knowledge of these char-
acteristics when prescribing and dispensing restricted the
role of healthcare professionals in this area. They did,
however, highlight the potential for improved involve-
ment via increased collaboration with carers and by
actively enquiring about difficulties. Due to the qualita-
tive nature of this study, the extent to which results can
be generalised to the wider older adult population is
limited. However, the study has key implications for the
future role of healthcare professionals in the provision
of patient centric drug products.
Conclusion: Drug manufacturers should consider physi-
cal attributes during drug development to ensure opti-
mum patient adherence and reduce the potential for
medication errors. Future work taking into account the
views of the industry on this topic will help to further
inform the development of patient centric drug products
for older people. However, in order to ensure these are
then prescribed and dispensed appropriately, the role of
health and social care professionals must further be
defined and explored.
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Introduction: Pharmacists’ recommendations to physi-
cians concerning medication appropriateness signifi-
cantly reduce potentially inappropriate prescribing,
adverse drug reactions, and medication-related readmis-
sions in hospitalised older adults. Intervention studies
with a high proportion of prescribing recommendations
implemented are more likely to result in better patient
outcomes than those with lower rates of implementa-
tion, which typically result in non-significant differences
in patient outcomes. Reasons for non-implementation of
pharmacist recommendations must be identified and
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overcome in order to improve the delivery of pharmacist
interventions in the interests of patient safety and
improved patient outcomes.
Aim: The aim of this study was to explore the views of
pharmacists and physicians to identify the key factors
affecting physician implementation of pharmacists’ med-
ication appropriateness recommendations in hospitalised
older adults.
Methods: Semi-structured face-to-face interviews based
on the Theoretical Domains Framework (TDF)1 were
conducted with hospital pharmacists and physicians
who provided care to older adults in two acute univer-
sity teaching hospitals in the Republic of Ireland
between August 2018 and August 2019. Participants
were purposively sampled based on years of post-qualifi-
cation experience, and were recruited via email, text
message, or face to face at their place of work using a
combination of convenience sampling and snowballing.
The interviewer had no previous relationship or estab-
lished rapport with any of the interviewees prior to
study commencement. Interviews were audio-recorded
and transcribed verbatim. Content analysis was
employed to identify the key themes and predominant
TDF domains that influence physician implementation
of pharmacist recommendations.
Results: Interviews were conducted with 6 pharmacists
and 8 physicians, with an average interview length of
33 minutes. Five key factors were found to affect physi-
cian implementation of pharmacist recommendations: i)
Clinical relevance and complexity of the recommenda-
tion: recommendations of higher priority and those that
do not require complex decision-making are implemented
more readily. ii) Inter-professional communication: rec-
ommendations provided verbally, particularly those com-
municated face to face with confidence and assertiveness,
are more likely to be implemented than written recom-
mendations. iii) Physician role and identity: the grade,
specialty, and personality of the physician significantly
affect implementation. iv) Knowing each other and devel-
oping trusting relationships: previous acquaintance and
the development of inter-professional trust and rapport
greatly facilitate recommendation implementation. v)
Hospital environment: organisational issues such as docu-
mentation in the patient notes, having the opportunity to
intervene, and the clinical pharmacy model all affect
implementation.
Conclusion: This is the first study to evaluate the under-
lying behavioural determinants affecting physician
implementation of pharmacist recommendations con-
cerning medication appropriateness in older adults. The
utilisation of the TDF in formulating the topic guides
and analysing the transcripts revealed additional themes
that would otherwise not have been identified. However,
acknowledging that participants were recruited from just
two Irish hospitals and that different clinical pharmacy
models exist, the key factors affecting recommendation
implementation identified in this study may not be
transferable to all hospital settings. Nevertheless, the
study findings will likely aid in the development of theo-
retically informed interventions with increased physician
implementation of pharmacist recommendations, aiming
for significant improvements in both medication appro-
priateness and clinical outcomes for hospitalised older
adults.
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Introduction: Frailty is a geriatric syndrome in which
physiological systems have decreased reserve and resis-
tance against stressors1. Frail older people in acute care
who are taking multiple medicines (polypharmacy) are
at increased risk of potentially inappropriate prescribing
(PIP). A consultant/specialist pharmacist-led medicines
optimisation service (Medicines Optimisation in Older
People [MOOP]) has demonstrated improved prescribing
appropriateness and medication cost savings in interme-
diate care in Northern Ireland2. This model has been
adapted for frail patients and is currently being rolled
out to patients admitted to a frailty ward in one hospi-
tal in Northern Ireland.
Aim: To evaluate the impact of the MOOP model on
outcomes for frail older people admitted to the acute
care setting.
Method: The following data were extracted from a data-
base of routinely collected data for patients enrolled into
this service from 1st May 2019 onwards: demographics;
NHS resource utilisation; length of stay; frailty score;
falls data; medication data; number of medications pre-
scribed. Medication Appropriateness Index (MAI),
AntiCholinergic Cognitive Burden (ACB) score, Anti-
cholinergic Effect on Cognition (AEC) score and falls
risk were calculated. Based on these baseline parameters,
individualised pharmaceutical care plans were imple-
mented. Clinical interventions were graded using the
Eadon criteria and cost savings were estimated using the
ScHARR model. Statistical analysis was undertaken
using SPSS; the Wilcoxon signed ranks test was used
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(P ≤ 0.05 considered significant). The Hospital Trust
Innovation, Research and Development team confirmed
that ethical approval was not required, as this was a ser-
vice evaluation.
Results: Data collection is ongoing. Seventy-two
patients were recruited into the service as of mid-Sep-
tember 2019, aged between 71–98 years (mean age
85.0  6.1 years), the majority (77.8%) were female,
56.9% were admitted with a history of falls or because
of falls, and 22.2% of patients had fragility. Most
patients (84.7%) had mild to severe frailty (Clinical
Frailty Scale 5–7). Almost all (97.2%) had polyphar-
macy, and about half (48.6%) had two frailty syn-
dromes (polypharmacy, immobility, incontinence,
delirium/cognition issues, falls). The most common com-
bination of frailty syndromes (27.8%) was polyphar-
macy, falls and delirium. Of 380 interventions made
after medication review; 71.3% were assessed as having
an Eadon grade of 4 or more, indicating that these
interventions were significant and resulted in improved
care standards. A total cost saving of £54,467–£115,926
was made as a result of these interventions. As shown in
Table 1, specialist pharmacist-led medicines optimisation
resulted in a significant reduction in median scores for
MAI, ACB, AEC, falls risk, total number of drugs and
number of drugs associated with falls.
Table 1. Median scores for ACB, AEC, MAI, falls risk,
total number of drugs, and number of drugs associated
with fall before and after clinical pharmacist review.
Conclusion: These preliminary results demonstrate that
the MOOP service contributes to safer and more appro-
priate prescribing for frail older people in acute care as
well as demonstrating medication cost savings. The
strength of this study lies in the combination of different
clinical parameters to evaluate prescribing appropriate-
ness. It is limited by being performed in a single ward in
one hospital.
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Pharmacist Prescribing
Clinical supervision for nurse and
pharmacist independent prescribers:
a Delphi study
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Introduction: Previous research by the authors found
that the clinical supervision of nurse (NIP) and pharma-
cist (PIP) independent prescribers in primary care in
Wales was variable. Most clinical supervision was infor-
mal in structure and, in some cases, ad-hoc. Findings
suggested that formal clinical supervision is preferred
yet is not readily available. Exploring the perception of
the ideal purpose, content and structure of clinical
supervision is imperative to creating a usable model to
improve the quality of clinical supervision.
Aim: To identify if there is consensus amongst NIPs
and PIPs on the purpose, content and structure of effec-
tive clinical supervision and, if so, on what parameters
there is agreement.
Methods: A two-phase E-Delphi survey was conducted
using the platform Online Surveys with an expert panel of
primary care NIPs and PIPs. The inclusion criteria were:
a UK qualified NIP or PIP, currently employed in a pri-
mary care prescribing role without necessarily prescrib-
ing, NHS employed or NHS contracted and working in
Wales. Participants who participated in the first phase of
this research were initially approached. They were identi-
fied by NHS gatekeepers (nurse and pharmacist prescrib-
ing leads) across the seven Welsh Health Boards. Social
media was used to recruit other participants that met the
expert panel criteria. The descriptors used in the survey
were informed by earlier qualitative research. The surveys
included quantitative ratings and open text comments.
All survey responses were anonymised with consent
implied by return of the survey. The survey consisted of
two rounds. Findings were analysed using descriptive
statistics for quantitative findings and content analysis for
open text responses. Interquartile ranges (IQR) were used
for determining the level of consensus with an IQR < 1
defined as consensus, an IQR between 1–2 was reviewed
and an IQR > 2 defined as no consensus.
Results: 22 participants (15 pharmacists and seven nurses)
were recruited from all seven Welsh Health Boards. 22
responded to round one (100%), 16/22 (73%) responded
to round two. The descriptors were divided into three cate-
gories: purpose, content and structure. Of the 16 descrip-
tors in round 1, eight met consensus (and not included in
round two). Round two had eight descriptors and consen-
sus was met on four. An example of a descriptor that met
consensus under each category is listed in table 1. Findings
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suggested that clinical supervision should be available at
whatever level the supervisee feels is appropriate. Partici-
pant findings also suggested that the purpose, content and
structure of clinical supervision should not reinforce a
supervisor dominant structure.
Table 1. Examples of descriptors
Purpose “The purpose of clinical supervision is to support me in
my clinical practice”
Content “Reflection on clinical practice should be a key part of
clinical supervision”
Structure “There needs to be flexible guidance for clinical
supervision sessions so independent prescribers can to
access appropriate support for their needs”
Conclusion: This is the first study to identify the level of
consensus amongst NIPs and PIPs on what is required for
effective clinical supervision. This study was limited by the
small number of participants and that it was conducted
solely in Wales. The findings will inform a model of clinical
supervision to support an inclusive and supportive clinical
supervision session which is both flexible and user-friendly
to suit the diversity of prescribers in primary care. Future
work will explore stakeholders’ views on the clinical super-
vision model so it can be used in practice.
Independent pharmacist prescribers’
views of their role as prescribers in
primary care settings in Wales
S. Alghamdi, R. Deslandes and K. Hodson
Cardiff University, Cardiff, UK
Introduction: Since 2015, the number of independent
pharmacist prescribers (IPPs) in primary care in Wales
has increased greatly. This is due to the implementation
of the Primary Care Plan in Wales 1 and primary care
clusters 2, which aimed to train more non-medical
healthcare professionals, including pharmacists, as inde-
pendent prescribers. This initiative hoped to increase
patients’ access to treatment, improve primary care ser-
vices, and relieve pressure on General Practitioners
(GPs). The views of IPPs regarding their role as pre-
scribers in primary care in Wales are important to
inform future developments and to understand this
advancement within pharmacy practice. No other
research has previously been undertaken on to investi-
gate the role of IPPs in primary care in Wales.
Aim: To describe the role of independent pharmacist pre-
scribers working within primary care in Wales and to explore
their views on how their role is embedded in primary care.
Methods: Semi-structured telephone interviews were con-
ducted with IPPs working in primary care settings from
all seven health boards (HB) in Wales. Ethical approval
was obtained from the Cardiff School of Pharmacy and
Pharmaceutical Sciences. Purposive sampling was used to
recruit all the participants who met the inclusion criteria
of this study. An invitation email, participant information
sheet and consent form were sent to potential participants
by gatekeepers. These were directors of independent phar-
macist prescribing courses, pharmacist leads in each HB,
local primary care pharmacist leads and the Pharmacists
in Practice: All Wales Community of Practice (PIPCOP)
event director in Wales. Written consent was obtained
from participants. Interviews were audio-recorded and
transcribed ad verbatim. Thereafter, thematic analysis
was used to analyse the data.
Results: Interviews were conducted with 10 IPPs, which
lasted between 33 and 78 minutes. Six themes emerged
from the data, including their role as an independent
prescriber, change in the role over time, satisfaction in
the role, perceived benefits of the role, and the facilita-
tors and barriers to the role. All participants perceived
their role as prescribers positively. However, some
reported the topic of indemnity as a barrier and they
required more clarity in terms of what they are covered
to prescribe and to do. Conflicting views were reported
about working within more than one general practice as
some perceived it positively as it increased their experi-
ence and scope of practice. Whereas, others perceived it
as a barrier as they thought that it lacks the continuity
of practice and found it difficult to build new relation-
ships with other healthcare professionals.
Conclusion: This study is the first qualitative study to
explore the views of IPPs regarding their prescribing
role in primary care in Wales. It revealed important
themes that could be relevant to all IPPs working in the
primary care sector across the UK. A study limitation is
that interviews were conducted over the telephone,
which lacks the face-to-face communication that could
help in building a rapport with participants in order to
obtain more details. Future work should focus on
exploring views of the stakeholders who work with IPPs
regarding their role as prescribers.
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Community pharmacists’ experiences of
undertaking an IP qualification – a
qualitative analysis
C. Tierney
University of Sunderland, Sunderland, UK
Introduction: Non-medical prescribing began in the Uni-
ted Kingdom with the launch of the Supplementary Pre-
scribing qualification in 2003, followed by the addition of
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the Independent Prescribing qualification in 20061. Since
the introduction of these qualifications, uptake amongst
community pharmacists has been relatively low as high-
lighted by the General Pharmaceutical Council (GPhC)
Registrant Survey in 20132. As the demands and strains
placed upon the national healthcare system to provide
timely and efficient care increases, the need for indepen-
dent prescribers within the community sector is increas-
ing, in order to reduce the strain on other prescribing
healthcare professionals. Previous studies have not
addressed why community pharmacist enrolment on inde-
pendent prescribing courses is disproportionately low
compared to pharmacists from other sectors.
Aim: To examine community pharmacists’ experiences
of undertaking an Independent Prescribing qualification
at a UK university and the perceived barriers and facili-
tators to their studies.
Methods: A qualitative approach to data collection was
adopted through semi-structured interviews with phar-
macists either currently studying on or recently com-
pleted the Independent Prescribing qualification.
Twenty-eight potential participants were identified from
programme records with purposive sampling to select
only pharmacists from a community pharmacy back-
ground, and invited to interview. Interviews were con-
ducted in person at a venue chosen by the interviewee
or over the phone if more convenient to them and audio
recorded. Recordings were transcribed verbatim and
analysed using NVivo 11 software to code data and
explore emerging themes.
Results: Interviews took place with ten pharmacists.
Three main themes emerged from the analysis of the
transcribed interviews: A desire for career progression
versus a clear element of self-doubt in their ability to
succeed, financial barriers to study and career progres-
sion, lack of opportunities to use the qualification. The
experiences of the community pharmacists interviewed
were generally positive with the main driving force to
enrolment being the desire to further their knowledge
and advance their careers “The IP course was always
one I wanted to do and it was a kind of a natural progres-
sion from everything I’ve done to further myself”. Barriers
to their studies included lack of confidence and financial
issues arising from time away from work to attend uni-
versity and the compulsory hours with their designated
medical practitioner “So, there’s financial barriers for
community pharmacists. . .having time out of work to go
and study at university and then spend the time having
ninety hours’ worth of supervised training”. Lack of
opportunities to use the independent prescribing qualifi-
cation within community pharmacy is forcing pharma-
cists to work spilt sector or leave community pharmacy
altogether “To be honest, then I didn’t see really a way
that I would use it in community pharmacy”. Suggestions
to improve the independent prescribing course at the
university included increasing training on the diagnostic
element of consultations as community pharmacists
found this area challenging and the utilisation of phar-
macist independent prescribers during the teaching of
the course.
Conclusions: This study specifically explored community
pharmacists’ experiences of undertaking an IP qualifica-
tion at a UK university. Themes that emerged have the
potential to help educators better understand the rea-
sons why uptake amongst community pharmacists has
been historically low and how this can be addressed The
research was limited by the relatively small sample size
of students from one university, and therefore these
findings cannot be said to be representative of commu-
nity pharmacists around the UK.
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Wellbeing and Community Pharmacy
The current and potential role of
community pharmacy in asset-based
approaches to health and wellbeing:
a qualitative study
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Introduction: Health assets can be conceptualised as col-
lective resources, including relational, social, environ-
mental, and physical facets that foster the welfare of
individuals and communities.
Asset-based approaches aim to improve wellbeing,
protect against ill-health, and reduce health inequalities
by capitalising upon existing assets, strengths, and
resources of individuals and communities, as opposed to
focusing upon needs and deficits. Asset-based
approaches are increasingly used as a basis for public
health initiatives and as a framework to support the
transformation of health and social care services1. To
date, there has been scant consideration of the potential
role for community pharmacy.
Aim: To explore the current and potential role of com-
munity pharmacy in asset-based approaches.
Methods: Participants included community pharmacy
practitioners and project leads, and public health policy
and strategic leads from across the UK. Participants were
recruited purposefully through local networks and social
media for qualitative semi-structured telephone interviews
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between June and October 2019. Transcripts were anal-
ysed inductively using simultaneous inductive open cod-
ing and deductive coding using Theory of Change2.
Results: Fifteen participants were interviewed. Pharmacy
participants conceptualised their current and potential
involvement in asset-based approaches at the level of
working with individuals or communities. On an indi-
vidual level, asset-based approaches were understood as
the adoption of increasingly person-centred and
strength-based approaches towards consultations with
patients and customers. At a community level, asset-
based working was seen as the ‘contribution’ that phar-
macies made, or could make, to the communities in
which they were situated beyond current standard com-
missioned services. This contribution was often aligned
with the notion of strengthening social capital and non-
medicalised approaches to enhancing individual and
public wellbeing. The adoption of asset-based
approaches was felt to have reciprocal benefits for indi-
viduals, communities, the pharmacy workforce, and the
pharmacy profession. There was limited evidence of a
systemic adoption of asset-based working within the
pharmacy sector. The changing landscape of community
pharmacy practice and shift towards patient-facing clini-
cal roles was felt to offer expanded relational opportuni-
ties to engage and collaborate with individuals,
communities, and other stakeholders. The adoption of
asset-based approaches was challenged or enabled by a
number of factors including the availability of protected
time and resources, workplace and organisational cul-
ture/values, strategic leadership, commissioning, funding
arrangements, and lack of community pharmacy pres-
ence within primary care networks. Interviewees sug-
gested opportunities to support integration, including
further development of ‘healthy living pharmacies’,
resources to support pharmacy teams to develop collab-
orative relationships with other organisations/sectors,
greater access to and inclusion in local asset maps/direc-
tories, and a programme of enabling funding. Further
exploration of community pharmacies’ potential involve-
ment in non-medicalised approaches to improving well-
being, including social prescribing, were also suggested.
Conclusions: Whilst small-scale, this is the first study to
explore asset-based approaches within the context of
community pharmacy. The study provides valuable
insights into the potential for community pharmacy to
support the health and wellbeing of individuals and
communities and play a more central role in the reduc-
tion of health inequalities, by incorporating and con-
tributing to asset-based approaches in their localities.
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A UK-Japan comparative qualitative
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Introduction: Japan and the United Kingdom (UK) face
significant healthcare challenges due to an ageing popu-
lation. Both governments are keen to promote commu-
nity pharmacies (CPs) as health and wellbeing hubs. In
Japan, ‘community-based integrated care systems’ have
been implemented focusing on the prevention in com-
munity, embedding CPs as ‘Health Support Pharmacies
(HSP)’1. The UK has nationalised the ‘Healthy Living
Pharmacy (HLP)’ scheme, aiming to better use CP for
improving public health and redress health inequalities2.
The aims of both HSP and HLP are similar; however,
their approaches differ in terms of service delivery.
Aim: The study aim was to explore and compare lived
experiences of pharmacists in the delivery of the HSP in
Japan or HLP in the UK, to inform further improve-
ment of public health services in both countries.
Methods: Semi-structured interviews were conducted in
Japan and the UK with pharmacists working either in
HSP or HLP. The ethical approval was obtained from
the Research Ethics Committees of the University. Pur-
posive sampling was applied to reach registered pharma-
cists working in HLP/HSP that have obtained HLP/
HSP accreditation, via professional networks, targeting
15 participants from each country, or until data satura-
tion was reached. An interview schedule was developed
by NA and face validated in the research team, includ-
ing career background, pharmacy-staffing, engagement
with and impact of HSP or HLP, challenges of service
delivery, and further improvement. The interviews were
conducted in Japanese and English, as appropriate.
Consent was obtained from all participants before inter-
views. Interviews were audio-recoded and transcribed
verbatim. Transcribed Japanese interviews were trans-
lated into English using forward-backward translation
method. Transcribed data were analysed thematically.
Results: 16 interviews in Japan were conducted in July and
August 2018, and 15 interviews in the UK between April
and August 2019. Five themes emerged regarding chal-
lenges in HSP/HLP provision; understanding concepts of
schemes, training, awareness of services and pharmacist’s
role, sustainability of services, and access to services and
information. Of the five themes, ‘sustainability of services’
was strongly concerned both in Japan and UK. Further,
five themes emerged for further improvements in HSP/
ªThe Authors. IJPP ª 2020 Royal Pharmaceutical Society International Journal of Pharmacy Practice, 28 (Suppl. S1), pp. 4–43
22 International Journal of Pharmacy Practice 2020; Supplement S1
HLP including; professional development, raising aware-
ness of services and pharmacist’s role, securing resources,
systems and regulations, and innovation. Opinions related
to ‘securing resources’ theme have significant difference
between Japan and UK, as HSP in Japan is not linked with
remuneration and requires extra funding. Whilst the UK
also struggle securing funding, although overall service
quality associated remuneration was addressed.
Conclusion: This is the first study to compare pharma-
cists’ experiences in health and wellbeing functions of
CP in the UK and Japan. Different service requirements
and delivery between HSP and HLP limit the interpreta-
tion of direct comparison of pharmacists’ experiences.
However, the study indicates varying experiences under
the common themes, according to their levels of imple-
mentation and understanding of services of individual
pharmacists and pharmacies in each setting. Future
work includes developing recommendations to each
country from their experiences of different approaches
towards health and wellbeing hub functions in CP.
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The design and delivery of a community
pharmacy-based positive psychology
intervention: a feasibility study
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Introduction: Community pharmacy (CP) has been
recognised as providing an appropriate setting for public
health interventions. With recent policies focusing on
enhancing the health and well-being of the population
in Wales1,2, this research applies positive psychology
(PP) to the design of a well-being intervention. The goal
of PP is to redirect attention away from pathology, dis-
ease and weaknesses towards the study of human flour-
ishing. This study is part of a larger programme of
research to design and test the implementation of a
pharmacy-based well-being service.
Aim: To explore the views of key informants and stake-
holders on the feasibility of implementing a positive psy-
chology intervention (PPI) in a CP setting.
Methods: The Medical Research Council (MRC) frame-
work for complex interventions was used as the basis
for the study design. This paper focuses on Phase 2,
‘Feasibility and Piloting’. Phase 1 involved modelling of
the intervention based on theory and several iterations
to develop the PPI (Table 1) to be tested in one inde-
pendent CP in a deprived area of South Wales.
Table 1. Summary of the design of the PPI
Timeframe
Type of
Session Structure
Title of
Deliverer
Six weekly
sessions plus
one follow-up
over a total
eight weeks
One to one,
30–
45 minutes
in length
Seven one-to-
one Sessions
plus diary to
be completed
3 days a week
Wellbeing
Facilitator
A semi-structured interview schedule was designed to
capture participants’ views about the PPI, covering
seven broad areas. Key informants were approached
due to their in-depth knowledge of healthcare, public
health or community pharmacy systems in Wales. Stake-
holders were either staff members at the CP study site,
general practitioners or well-being professionals working
within the local community. Interviews were audio-
recorded, transcribed verbatim and analysed using a
combination of framework and thematic analysis.
Results: Fifteen semi-structured interviews were con-
ducted (seven key informants; eight stakeholders). Seven
overarching themes emerged from the data. These were
(n = number of sub-themes) related to: 1) Intervention
design (n = 6; overall impression, views on diary, session
duration, concepts, timeframe, one to one consultation),
2) Title of the wellbeing facilitator (n = 2; overall
impression, suggestions), 3) Identifying the target popu-
lation, with suggestions, 4) Recruitment (n = 4; commu-
nity, community pharmacy, self-referral, mixed-referral),
5) Factors to support implementation (n = 4; evaluation
process, wellbeing facilitator, community pharmacy, par-
ticipant), 6) Challenges to implementation (n = 3; partic-
ipant, wellbeing facilitator, community pharmacy) and
7) Impact of the intervention (n = 3; community wellbe-
ing, community healthcare services, community phar-
macy).
Conclusions: Overall, the feedback from the interviewees
was positive and the findings supported the use of a CP-
based setting for implementing a PPI with the appropri-
ate infrastructure in place. The findings from this phase
will be utilised to inform the design and delivery of the
PPI, with further feasibility testing within Phase 3 of the
MRC framework. The study setting is limited to one
independent CP which may not be representative of all
pharmacies in Wales, however, these preliminary find-
ings can be used to support future research.
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Co-designing Interventions
Co-design of a new community
pharmacy delivered text message
intervention with patients and
professionals to support medicines
adherence
G. Donovan1, N. Hall1, J. Ling1, F. Smith2 and
S. Wilkes1
1University of Sunderland, Sunderland, UK and 2University College
London, London, UK
Introduction: It is estimated that 30%–50% of patients
do not take medicines as prescribed. Medication tak-
ing can be described as a behaviour, at which beha-
viour change techniques (BCTs) could be applied.
Text messages have been highlighted as a potential
tool to support medicines adherence and could
incorporate BCTs to support this. A face-to-face com-
ponent may also be required alongside digital commu-
nication to address wider barriers to medicines taking.
This support has been previously been delivered by
community pharmacists in services such as medicines
use reviews. It is important that stakeholders and
intended recipients of new interventions are involved
in any design process.
Aim: To co-design a personalised two-way automated
text messaging intervention combined with a community
pharmacy consultation to support medication adherence.
Methods: A human-centred design (HCD) approach
was used1. Six prototypes were developed based on a
systematic review. Three of these were presented to
patients, including a personalisation questionnaire,
patient information leaflet and video of an introduction
to the intervention in a community pharmacy. A further
two prototypes were presented to professionals including
two diagrammatic representations, one of how the ques-
tionnaire would personalise the text message interven-
tion and a second which suggested how the intervention
could be integrated into existing care pathways. Both
groups were also shown a video of a consultation incor-
porating the intervention with a community pharmacist.
Nominal group technique was used as a framework to
gather feedback for the co-design process. This used
focus groups with patients and professionals to generate
24 International Journal of Pharmacy Practice 2020; Supplement S1
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statements about the prototypes; items that participants
liked and items that they felt needed to be changed.
These were summarized and formulated into a ranking
questionnaire which was then sent out to all participants
either on paper or online.
Results: Nine patients and 21 healthcare professionals
(pharmacists, nurses, general practitioners) were included
in the co-design process across five focus groups. 17 par-
ticipants also took part in the ranking exercise. The
design concept was positively received by all participants.
A summary of the highest ranked statements can be
found in Table 1. There was agreement that a pharmacy
setting and a review by a pharmacist was desirable by
both patients and professionals. Changes suggested by
patients also included ensuring that recipients understood
that communication was automated during the consulta-
tion. Professionals additionally liked the range BCTs
included in the intervention, especially the support for
habit formation. However, they felt uncomfortable with
the use of more negatively framed BCTs and wanted more
support included for patients to use home monitoring
equipment. Changes highlighted as part of the co-design
process have now been incorporated into a final design
which is undergoing ‘live’ prototyping as part of the next
cycle of the HCD process.
Conclusions: HCD methods were effective for support-
ing a co-design process to assess initial acceptability of a
new behavioural intervention to support medicines
adherence. Other researchers may also find HCD meth-
ods helpful as for co-production of interventions with
patients and professionals. The intervention ultimately
will also require testing for effectiveness using a clinical
trial design.
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The development of pictograms to
illustrate women’s experiences with
adjuvant hormone therapy for breast
cancer
O. AlOmeir, N. Patel and P. Donyai
University of Reading, Reading, UK
Introduction: Breast cancer is the most common type of
cancer diagnosed in the UK, accounting for 30.8% of all
malignant female cancer registrations in 2016 (1). The
treatment includes the use of long-term endocrine therapy
in hormone receptor (HR) positive cases, which account
for two thirds of all breast cancer diagnoses. Despite its
importance research has shown a reluctance by some
women to fully adhere to such long-term treatment (2).
The author conducted a grounded theory (GT) synthesis
to integrate data from existing qualitative studies about
women’s adherence to hormonal treatment in breast can-
cer to develop an in-depth explanatory model of medica-
tion experiences in this condition. Afterwards, the author
conducted a GT based interview study with women who
have been taking hormone therapy following a breast
cancer diagnosis. The results combined from both studies
led to the development of an all encapsulating GT with
three main categories; 1) The treatment of breast cancer:
prescription of a long-term drug; 2) The treatment of
breast cancer: adhering to the long-term treatment; 3)
The treatment of breast cancer: stopping the long-term
treatment. These categories were represented using com-
plex tables but needed to be simplified if they were to help
patients in the future.
Aim: To develop the GT categories into a set of three
pictograms and validate these with survivors.
Methods: The pictograms were developed by the author
in consultation with their supervisor. Essentially, each
of the main categories was represented by one overall
pictogram showing the patient journey with a series of
small labelled drawings. The pictograms were validated
for accuracy and meaning by an independent group of
researchers (n = 10) who acted as reviewers by complet-
ing a content validity questionnaire. The Content Valid-
ity Index (CVI) was the proportion of researchers who
agreed that the labelled drawing represented a detailed
description given alongside it (taken from the original
GT model). After making revisions that were acceptable
to the 10 reviewers, the finalized pictograms were dis-
cussed with breast cancer survivors (n = 12) whose
responses were obtained in interviews. They were asked,
for example, if the pictograms encapsulated their own
experiences.
Results: Of the 76 labelled drawings, 13 had an
CVI < 0.8 and were therefore modified. The finalized
versions elicited positive responses from the survivors,
with all 12 reporting that their own experiences were
captured well by the pictograms. For example, “I think
that sums it up very well and actually it’s helped me to
tell you more about my treatment cycle” and “Year.
That is me to a tee. That’s quite scary. Yeah, that is
quite scary.” This gave the respondents some comfort
that they were not alone in experiencing difficulties with
their treatment.
Conclusion: The developed pictograms were found to be
helpful by breast cancer survivors and therefore have
the potential be useful when communicating with new
patients as they embark on hormonal treatment for
breast cancer. Future research should assess the applica-
bility of these pictograms in a clinical setting, which is
yet to be tested and is a weakness of the current work.
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Early Careers
Multi-sector pre-registration training:
qualitative analysis of pre-registration
trainees’ perceptions of a pre-
registration training programme in
academia and community pharmacy
K. Davison1, A. Sturrock1, J. Hardisty1 and K.
Bullen1,2
1Univeristy of Sunderland, Sunderland, UK and 2MD&AG Burdon Ltd,
Gateshead, UK
Introduction: Multi-sector pre-registration training is
continually evolving and has become a popular choice
for trainees1. In 2013 the University of Sunderland
developed a novel pre-registration training programme
in collaboration with a regional community pharmacy.
Since that time fourteen trainees have successfully
completed the training but no formal evaluation has
been previously conducted. This study explores the
experiences of pharmacists having undergone such
training.
Aim: To explore retrospective perceptions of registered
pharmacists towards their experiences of pre-registration
training across academia and community pharmacy and
to understand the benefits and limitations of such train-
ing. A focus was also placed on establishing trainees’
self-perceptions of preparedness to practice after under-
going this training.
Methods: A purposive sample of registered pharmacists
(n = 12) who undertook a pre-registration training pro-
gramme in academia and community pharmacy between
2013 and 2019 participated in one to one semi-struc-
tured interviews. A recruitment email with details of the
study was sent to potential participants (n = 14) who
had completed the training programme during the speci-
fied timeline. Consent was obtained from participants
prior to interview. The topic guide was designed by the
project team to explore the positive and negative experi-
ences of the training programme and perceptions of the
participants’ preparedness to practice. Interviews were
conducted over the telephone by an independent
researcher. Interviews were audio recorded, transcribed
verbatim and thematic analysis was conducted using a
framework approach.
Results: Thematic analysis highlighted three key themes
with a range of sub-themes (see Table 1).
Table 1. Results of thematic analysis
Theme Sub-theme
Supervision Wide exposure to pharmacists
from different practice
backgrounds was identified as
an influencing factor that
helped the trainees develop
Continuous feedback from these
supervisors enabled increased
reflection and professional
development
Self-confidence Participants discussed the
responsibility they felt to help
others learn and how that
encouraged their own
personal progression
The self-imposed pressure to
impress academic staff and
integrate into an academic
team served to enable a
higher level of personal
development
Participants perceived an
increased preparedness to
practice in comparison to
their peers in single sector
training
Meeting demands Communication barriers
between the different sites led
to participants feeling ‘caught
in between’ the two
Balancing the requests and
expectations of different
training sites was also
highlighted as an additional
pressure not experienced in
single sector training
A high level of maturity in participants’ responses
was also identified by researchers, potentially attributa-
ble to an obvious self-motivation to improve and
achieve.
Conclusion: Stakeholders involved in pre-registration
training and delivery of pharmacy education may find
the results of this study informative and could poten-
tially use the findings to influence development of fur-
ther future multi-sector pre-registration training
programmes involving academia. Multi-sector pre-regis-
tration training has been explored previously across hos-
pital pharmacy, community pharmacy and general
practice2, but there is a paucity of evidence regarding
training in academia. The participants in this study per-
ceived their training experience as being extremely posi-
tive with all participants stating they would encourage
others to undertake similar training. The participants in
this study had been selected as suitable trainees for a
multi-sector post based on academic ability and personal
attributes so were by default likely to be highly moti-
vated individuals.
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Understanding the transition
experiences of foundation (early career)
pharmacists within Great Britain (GB)
H. Chang and I. Bates
University College London, London, UK
Introduction: There is growing consensus internationally
that healthcare professionals should not be trained for
specific jobs, but to be flexible and adaptable. This
approach will enable pharmacists to better respond to
and meet the complex pharmaceutical care needs of
patients and the public1. Structured developmental path-
ways underpinned by evidence-based frameworks can
facilitate the creation of a safe and effective pharmacist
workforce that can better respond to future healthcare
challenges. Development programmes for foundation
pharmacists (FPs) at postgraduate level are still being
refined, and no unified model for all pharmacy sectors
exists. There is a need to understand how pharmacists
develop and progress in their careers and professional
practice, in particular their transition experiences, where
evidence is limited.
Aim: To explore the professional development transition
experiences of FPs undergoing structured work-based
training.
Methods: A purposive sample of FPs working across
community and hospital pharmacy within GB were
recruited. Details of the study were shared on professional
networks, social media and through gatekeepers. A topic
guide was developed and piloted with 5 FPs. Semi-struc-
tured telephone interviews were conducted with 11 FPs,
which lasted between 30 and 80 minutes. The interviews
were audio-recorded, transcribed verbatim, coded using a
grounded approach and thematically analysed using a
constant comparison method2, in NVivo v12.
Results: The emerging themes were: individual develop-
ment outcomes; organisational challenges to develop-
ment; and a need for additional support. Participants
reported positive changes in their confidence and clinical
knowledge, which were attributed to a structured training
programme and a supportive environment “there’s an
aura of supporting you to do what you want to do”. How-
ever, there was a sense from some FPs that these improve-
ments also developed over time with experience “in
hindsight [the programme] has helped me, but I don’t think
it would be any different if I completed it or not”. A lack of
time, excessive workload and inadequate support and
feedback were reported as barriers to professional devel-
opment. Furthermore, participants recognised the impor-
tance of learning and continual development and its
contribution to patient care “from a patient point of view,
I think I’d rather be seen by someone who has [completed
training] than not”. There was acknowledgement that fur-
ther support for development at postgraduate level is
required, including support from experienced colleagues,
and guidance from pharmacy organisations.
Conclusions: To the best of our knowledge this is the
first qualitative study exploring the transition experi-
ences of FPs undergoing structured work-based training.
Preliminary findings suggest FPs benefit can be better
supported with challenges of transition. It is important
to recognise that the findings of the study may not gen-
eralisable due to the small sample size. This study is
part of a wider project; findings will be triangulated with
findings from a knowledge acquisition study to build a
picture of developmental pathways and transitions for
FPs. This will enable policy makers, training providers,
and educational bodies to develop programmes to sup-
port the transformation of a pharmacist workforce
equipped for the future.
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Introduction: There are well-established benefits from
reporting medication errors and identifying patterns to
help prevent future harm. In the UK, prescribing errors
originating from general practice and other community
services are often identified and rectified within commu-
nity pharmacy. Organisational structures within NHS
primary care mean that boundaries between these inde-
pendent organisations may act as barriers to error
reporting and associated learning.
Aim: To identify key facilitators and barriers to cross-
organisational prescribing error reporting and learning
across primary care and to explore the role of commu-
nity pharmacy within this.
Methods: Qualitative semi-structured face-to-face and
telephone interviews were conducted with a purposive
sample of pharmacists, prescribers and other key stake-
holders from across North East England. Interviews
explored: facilitators and barriers to prescribing error
reporting in primary care; the influence of decision-mak-
ing processes and healthcare context; and the role of
community pharmacy in optimising prescribing error
reporting and learning. Data collection and analysis
were underpinned by the Theoretical Domains Frame-
work (TDF)1. Framework analysis2 was used for coding
and charting the data with the assistance of NVivo soft-
ware (V12).
Results: Interviews included perspectives from primary
care prescribers (n = 11), pharmacists (n = 12) and other
key stakeholders (n = 12). Findings highlight how deci-
sion-making processes, practices and beliefs around pre-
scribing error reporting differ significantly across and
within different primary care organisations resulting in
variability in reporting and potential gaps in knowledge.
Emergent themes were mapped to the TDF. Social influ-
ences, environmental context and resources (e.g. organi-
sational cultures, local leadership and relationships,
heterogeneous regulatory and reporting processes and
systems, and beliefs about ownership, accountability
and responsibility) play a key role in the opportunities
and motivation to report prescribing errors. For exam-
ple, within general practice, approaches to risk manage-
ment were mainly described within “significant event”
and quality improvement paradigms. In community
pharmacy, the focus was on checking and rectifying
errors (rather than reporting) along with a clear distinc-
tion between the reporting processes associated with dis-
pensing and prescribing errors. Beliefs about
consequences of reporting also influenced reporting
behaviour (e.g. stigma and blame; compliance with regu-
latory and contractual frameworks; medico-legal issues;
impact on working relationships; and availability of
feedback and learning potential). Constraints on the
ability to report included: the ease of use of reporting
systems; conflicting workload pressures; and varied indi-
vidual interpretations of terminology, procedural knowl-
edge, potential significance and wider learning potential
associated with different types of prescribing errors.
Conclusion: There seems to be a lack of clarity and con-
sistency across primary care in relation to beliefs about
whose responsibility it is to report prescribing errors,
which errors should be reported, how, when and to
where. There was some acknowledgment of a potential
increased role for community pharmacy in the identifica-
tion of wider prescribing error patterns. Our findings
suggest that feedback and learning need to have a local
focus, be perceived to have positive and significant
potential to change practice, and be tailored appropri-
ately to each setting. Further research is required to help
identify consensus on how best to facilitate cross-organi-
sational knowledge sharing, learning and prescribing
quality improvement.
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Exploring the role of community
pharmacists in deprescribing
D. Kelly1,2 and L. Glynn1
1Graduate Entry Medical School, University of Limerick, Limerick,
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Limerick, Ireland
Introduction: Deprescribing is the planned and super-
vised process of stopping or reducing the dose of a med-
icine that might be causing harm or no longer providing
benefit. This idea has gathering interest over the past
decade due to growing concerns about the overuse of
medications and patient outcomes. As the primary pre-
scribers for most patients, physicians are the logical
health care practitioner to champion deprescribing.
Pharmacists scope of practice focuses on managing med-
ication therapy, therefore they may also contribute to
the deprescribing process.
Aim: The aim of the study is to explore how community
pharmacists in Ireland are involved in the deprescribing pro-
cess and to inform the design of interventions that could
enhance community pharmacists’ roles in deprescribing.
Methods: We used an explorative qualitative study
design, using semi-structured interviews with pharma-
cists based in the community in the Mid-West of Ire-
land. Community pharmacists were recruited through
purposive sampling to represent urban and rural set-
tings, years of experience and position as pharmacist
owner/manager or staff. We selected pharmacists who
varied with respect to important characteristics to allow
for comparison of data across different contexts and
participant characteristics to enhance understanding as
well as increase transferability of the findings.
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The interviews were conducted by phone, audio-
recorded and transcribed. Ethics approval for this study
has been received from University of Limerick Research
Ethics Committee (Education and Health Sciences).
Thematic analysis was carried out. Codes with common
features were grouped together as emerging themes,
before being assigned to overarching themes, describing
the phenomenon underlying the study.
Results: A total of 10 community pharmacists partici-
pated in semi-structured interviews. The themes identi-
fied include medication review and reconciliation,
relationship with local GPs, remuneration, access to the
patient’s medical file, experience of pharmacist, defined
scope of practice and workload. Medication reconcilia-
tion and medication information, and education were
considered positive roles for a pharmacist to perform
and within their scope of practice. Pharmacists reported
being proactively engaged in these roles and how medi-
cation reviews can occasionally involve recommending
deprescribing. The relationship with the GP was viewed
by interviewees as both a facilitator and a barrier to
pharmacist participation in deprescribing. Several phar-
macists in rural settings reported having limited capacity
to undertake new services. The introduction of some
form of remuneration for pharmacist medication reviews
or deprescribing services was collectively reported by
interviewees as an incentive for involvement.
Conclusion: This study highlights that deprescribing
linked to medication review is within the scope of prac-
tice of community pharmacists and there is potential for
community pharmacists to become more involved in this
area. Facilitators and barriers to integrating the service
into current community pharmacies were identified,
including lack of remuneration, which reflected health
system and policy barriers frequently reported in the lit-
erature in other jurisdictions. The importance of collab-
orative relationships with local GPs was also identified.
The small number of participants and the purposive
sampling from one geographic area may be a limitation
of the study. These findings may contribute to the devel-
opment of deprescribing services in primary care involv-
ing community pharmacists.
Technology
Impact of an electronic health record on
task time distribution in a neonatal
intensive care unit: a mixed methods
study
J. Devin1, J. Costello1, N. McCallion2,
E. Higgins3, B. Kehoe3, B. Cleary3 and
S. Cullinan1
1School of Pharmacy and Biomolecular Sciences, Royal College of
Surgeons in Ireland, Dublin, Ireland 2Neonatology Dept., The Rotunda
Hospital, Dublin, Ireland and 3Pharmacy Dept., The Rotunda Hospital,
Dublin, Ireland
Introduction: The Maternal and Newborn Clinical Man-
agement System (MN-CMS) project has introduced an
Electronic Health Record (EHR) to four Irish maternity
hospitals, with implementations planned for the remain-
ing fifteen units. The transition from paper-based to
electronic records represents a significant change in
workflow for healthcare professionals (HCPs). Previous
studies indicate that HCPs are concerned that EHRs
may decrease time for patient care by increasing time
spent on documentation and medication-related tasks1.
Aim: To determine the impact of an EHR on task time
distribution in a Neonatal Intensive Care Unit (NICU);
to determine the impact of the EHR on frequency of
contact with the ‘patient zone’ and frequency of inter-
ruptions to tasks; and to explore HCPs perceptions of
the EHR.
Methods: A mixed-methods, pre-post, time and motion
study in a 39-bedded tertiary level NICU was con-
ducted. Convenience sampling was used to recruit nurses
and doctors working in the NICU. Data were collected
by two independent observers in 8-week blocks, before
and after implementation of the EHR. An electronic
data collection tool was used to collate time spent on
pre-validated tasks related to direct care, professional
communication, reviewing of charts, documentation,
and medication-related tasks (2). Interruptions to tasks
and frequency of contact with the patient zone were also
quantified. Statistical significance was assessed using
two-sample proportion tests, two-sample t-tests, and
two-sample Wilcoxon rank-sum tests. A Bonferroni cor-
rection set significance at P ≤ 0.0025. Qualitative data
pertaining to participants’ thoughts on the EHR were
collected via survey and summarised using descriptive
statistics. Qualitative and quantitative data were triangu-
lated where appropriate.
Results: Forty-six NICU nurses and 17 paediatric regis-
trars were recruited over both phases, with 169.23 hours
data collected. There were non-significant changes in the
proportions of time spent by nurses on all tasks. Doc-
tors’ proportion of time spent on professional communi-
cation increased from 15.4% to 26.0% (P < 0.001).).
Significant increases to median task times were seen for
both doctors and nurses. Frequency of interruptions to
tasks decreased post-implementation (P < 0.001), as did
frequency of contact with the patient zone (P < 0.001).
The overall positive perceptions of the EHR identified
in phase 1 did not change significantly post-implementa-
tion, but usability issues were identified by individuals.
ICC values >0.80 were observed for each task category,
indicating good inter-rater reliability.
Conclusion: This was the first time and motion study to
quantify the impact of this EHR on NICU task time
distribution. Importantly, the EHR did not redistribute
time towards documentation and medication-related
tasks. Perceptions of the EHR remain largely positive
15 months’ post-implementation. Strengths of the study
include the pre-post design and validated data collection
tool. Limitations include the use of two data collectors,
although good inter-rater reliability was observed.
NICU-specific findings may not be generalisable beyond
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this setting. Findings have implications for future itera-
tions of MN-CMS by establishing a baseline for evalua-
tion. Recommendations include ongoing training and
support for clinical staff, and engagement with system
users to address usability issues and ensure quality of
care.
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Improving the discharge medicines
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Introduction: In 2011, the Welsh Government imple-
mented the Discharge Medicines Review (DMR) service
to reduce the risks associated with transfer of care. The
DMR initially involved paper transmission of discharge
information to community pharmacy with a follow-up
adherence support service, updated in 2015 to allow
electronic transmission of discharge information1. Other
localities in the UK have developed their own technol-
ogy-supported transfer of care systems: Refer-to-Phar-
macy (RTP), PharmOutcomes and Help for Harry
(HFH)2.
Aim: To compare and contrast UK technology-sup-
ported transfer of care systems in order to highlight
areas of good practice that can be used to recommend
improvements for the DMR service.
Methods: A generic qualitative methodology was
applied with semi-structured interviews, utilising an
interview guide informed by literature. Purposive sam-
pling identified four participants for their role in the
development and implementation of their respective
transfer of care2. Audio recordings were transcribed ad
verbatim and analysed deductively utilising thematic
analysis.
Results: Three interviews were undertaken including key
informants for DMR, RTP and PharmOutcomes.
Deductive analysis of the data revealed three broad
themes: implementation, system attributes and stake-
holder engagement. Aspects of implementation such as
the collaboration with local professional organisations
were the same across the systems. In contrast, only
RTP utilised a pre-determined marketing strategy
involving speaker circuits, publications and newsletters.
System attributes, such as the level of IT integration
were different across the systems, with DMR being the
most integrated hence saving stakeholder time and
allowing full data extraction. RTP and PharmOut-
comes notified community pharmacists of patient
admission and discharge whereas DMR only notified
on patient discharge.
In terms of stakeholder engagement, RTP provided
automated routine electronic feedback to hospital
pharmacists about the outcomes of the referrals and
hospital pharmacy staff using PharmOutcomes held
semi-regular meetings with hospital pharmacists to dis-
cuss high-level outcomes from referrals. DMR pro-
vides no regular feedback to hospital pharmacists.
Additionally, RTP and PharmOutcomes keep commu-
nity pharmacists accountable for referrals by accessing
a list of non-actioned referrals and following them up.
RTP is the only system to keep hospital pharmacists
accountable through staff-led meetings to discuss why
eligible patients weren’t referred. No new themes
emerged from subsequent inductive analysis of the
data.
Conclusion: The results suggest that while all systems
have the same aim, they have different methods of
implementation and provision. Good practice high-
lighted in this study that could be integrated into the
DMR system includes marketing strategies to advertise
the DMR and its benefits, increased accountability of
stakeholders in relation to referrals, integration of
patient admission notifications to community pharma-
cists and providing feedback to hospitals after a DMR,
in line with evidence from the 2014 service evaluation1.
The use of key informant semi-structured interviews
gathered a deep description of each transfer of care
system which was not found in literature. Results have
limited generalisability since only UK systems were
studied.
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General Practice Pharmacy
Community pharmacists’ experiences
with, views of, and attitudes towards,
general practice-based pharmacists: a
cross-sectional survey study
H.E. Barry, R. Clarke and C.M. Hughes
Queen’s University Belfast, Belfast, UK
Introduction: Regional five-year pilot schemes have been
introduced in the United Kingdom to embed pharma-
cists in general practices. In Northern Ireland (NI), it is
anticipated there will be 300 whole time equivalent prac-
tice-based pharmacists (PBPs) in post by 2020/211.
Whilst the evidence-base relating to PBP implementation
is growing, little is known about key stakeholders’ per-
spectives of the PBP role, and particularly those of com-
munity pharmacists.
Aim: To determine the nature and frequency of profes-
sional contact between community pharmacists and
PBPs, and to explore community pharmacists’ attitudes
towards and views of PBPs.
Methods: A questionnaire was mailed on two occasions
during February and March 2019, to all community
pharmacies in NI (n = 531). The questionnaire was
developed following a literature review and comprised
four sections. Section A collected sociodemographic
data about respondents and the community pharmacies
in which they worked. Section B determined the fre-
quency, methods, and nature of contact that community
pharmacists had with local PBPs. Section C explored
community pharmacists’ attitudes towards collaboration
with PBPs, using an adapted version of the Attitudes
Towards Collaboration Instrument for Pharmacists
(ATCI-P)2. Section D explored community pharmacists’
views about the PBP role. Responses were coded and
entered into SPSS v22. Descriptive analyses were used
where appropriate, and responses to open-ended ques-
tions were analysed thematically. Ethical approval was
obtained for this study.
Results: Two hundred and twenty-two community phar-
macists (41.8%) responded. The majority (68.5%,
n = 152) were employee pharmacists and had been prac-
tising as a pharmacist, on average, for 16.2 (SD 11.9)
years. Nearly all respondents (98.2%, n = 218) had been
in contact with a local PBP, with most (63.1%, n = 140)
in contact at least three times a week. A small propor-
tion of respondents (9.9%, n = 22) reported difficulty in
making contact with PBPs. Common reasons for con-
tact related to prescription queries or amendments to
prescriptions, unavailability of medications, and queries
related to hospital discharge. Whilst community phar-
macists displayed largely positive attitudes towards
collaboration with PBPs, 32.9% of respondents (n = 73)
showed disagreement or ambivalence to the statement
‘my role and the PBP’s role in patient care are clear’.
Many respondents agreed/strongly agreed that PBPs
could provide a better link to general practice for com-
munity pharmacists (84.2%, n = 187) and that the intro-
duction of the PBP role could have a positive impact on
patient outcomes (81.5%, n = 181). However, a large
proportion of respondents (85.5%, n = 190) showed dis-
agreement or ambivalence with the statement ‘patients
understand the difference between community pharmacists
and PBPs’.
Conclusion: This study has revealed that community
pharmacists are in frequent contact with PBPs about a
range of medication-related issues. Whilst there
appeared to be evidence of positive collaboration
between community pharmacists and PBPs, recognition
of individual roles was less clear which may impact
upon the successful integration of PBP within general
practice and primary care. The effect of non-response
bias may limit the generalisability of the findings to the
wider community pharmacist population in NI. Further
work to explore patients’ understanding and views of
pharmacist roles in primary care is needed to corrobo-
rate community pharmacists’ concerns.
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An Evaluation of a transition training
programme for pharmacists working in
GP settings
S. Bartlett and A. Bullock
Cardiff University, Cardiff, UK
Introduction: With an ageing population, increase in
chronic illness, complexity of medication and
polypharmacy, general practice surgeries struggle to
meet the health demands of today’s society1. This situ-
ation is exacerbated by a GP recruitment crisis. One
approach to alleviate such pressures and ensure the
provision of appropriate patient care is the integration
of pharmacists into the primary care skill-mix in GP
settings. Evidence from Scotland shows that this can
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free-up GP time and improve patient safety2. How-
ever, there is no research into this role across Wales.
Health Education and Improvement Wales (HEIW)
devised a new training programme to support pharma-
cists to transition into the GP setting. The 12-month
programme is centred on a competency-based frame-
work developed in partnership with the Royal Phar-
maceutical Society. Participants are supported by an
experienced GP pharmacist tutor for guidance and
competence assessment.
Aim: To ensure best patient care, pharmacists require
sufficient, relevant training for this GP practice-based
role. This study aimed to evaluate the new transition
training programme in Wales, reporting on whether it
adequately prepares pharmacists to show competence
for GP-based roles, programme strengths and limita-
tions and areas for development.
Method: Telephone interviews and focus groups were
conducted with all ten pharmacists enrolled on the
Welsh pilot programme (tutees) and their tutors. One-
to-one telephone interviews were held with tutees mid-
way through the transition programme and focus
groups with tutees and tutors towards the end of the
programme. All conversations were recorded and tran-
scribed. Data were coded in NVivo and analysed the-
matically.
Results: Five key themes were identified: pharmacists’
motives for working in GP settings and pursuing the
transition programme, learning and development needs
of tutees, experiences of the transition programme,
suggestions for programme improvements, and future
prospects. Tutees joined the programme with varied
previous experience; several with prior experience of
the general practice environment. Pharmacists chose to
make this transition for a variety of reasons, including
to further utilise their clinical skills and to work more
sociable hours. Tutees commonly desired to develop
their clinical and consultation skills, and more
broadly, their confidence and competence around
working in this different setting. The most valued ele-
ment of the programme was the tutor support, and
tutees particularly appreciated their tutor visiting them
in their own practice. Both tutees and tutors felt it
was important that the programme could be tailored
to match individual needs of pharmacists, particularly
given their varied prior experience and existing skills.
A flexible approach was welcomed and deemed essen-
tial. In terms of the future, tutees were looking to fol-
low a number of different career directions; several
intended to pursue the independent prescriber qualifi-
cation to further enhance their role and contribution
to patient care.
Conclusion: Although this study is based on self-report
and does not include formal performance assessments or
observation of practice, the programme appears to suc-
cessfully support pharmacist transition to working in
GP settings. It enables them to evidence their compe-
tence for this role. The tutor-tutee relationship is central
in supporting pharmacist development and achieving
role competencies.
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Evaluating community pharmacists’
perspectives of collaborative working
with GPs: a focus group study
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S. Chotai1, M. Tariq1 and S. White1
1School of Pharmacy and Bioengineering Keele University, Keele, UK
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Introduction: Inter-professional collaboration is defined
as “when multiple health workers from different profes-
sional backgrounds work together with patients, families,
carers (caregivers), and communities to deliver the highest
quality of care”1. Recent NHS strategy promotes the col-
laborative working of GPs and Community Pharmacists,
however historically, GP and Pharmacist collaborations
have been sparse, and barriers to collaborative working
have been widely reported in literature. A novel project
was designed to facilitate collaborative working between
GPs and Community Pharmacists, including an evalua-
tion to explore this further. The project included: dedi-
cated time to observe each other’s practices, leadership
training and a quality improvement project.
Aim: To evaluate Community Pharmacists perspectives
of collaborative working with GPs using a focus group
(FG) informed by a conceptual model of collaboration.
Methods: Following the six-month project, the GP-Com-
munity Pharmacist project participants (N = 10) were
invited via email to participate in a multidisciplinary FG,
using a pre-designed guide, informed by Bradley et al.
(2012) model of collaboration as the data collection tool.
Seven themes were covered2: locality, service provision,
trust, knowing each other, communication, professional
roles and professional respect. The FG was designed to
explore partner collaboration and shared understanding
of collaborative working within the GP-Community
Pharmacist project, thus it was decided to conduct this in
a multidisciplinary fashion. Data were audio recorded
and analysed using thematic analysis.
Results: Four GP-community pharmacist pairs partici-
pated in the FG. Themes related to barriers to collabo-
rative working were identified: Communication, IT,
Cost, Time, Insight to Professional Role, Trust and
Mutual Dependency and Education. Pharmacists dis-
cussed problems that could inform future education on
collaborative working; e.g. ‘one of the biggest barriers
would be changing mind-sets.’ Pharmacists also discussed
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their trust in GPs as being inherent, ‘the trust is always
there. Its inherent otherwise, we wouldn’t be where we are
at the moment.’ Pharmacists reported ‘I didn’t know what
it looked like from the GP side,’ and ‘I didn’t know that
they had all these extra bits they had to do,’ highlighting
lack of ‘Insight to Professional Role [of a GP]’ as a rea-
son for joining the project. Positive feelings about how
collaborations have strengthened throughout this project
were reported by pharmacists, e.g. ‘I have a better appre-
ciation of the challenges that the doctors face’ and ‘it did
break a lot of barriers because we’ve started to communi-
cate with the Practice Managers and the GPs a lot more.’
Conclusion: FG results highlight that this project,
through facilitating collaborative practice has: improved
both pharmacists’ knowledge and insight of the role of
a GP, highlighted that pharmacists feel they have trust-
ing relationships with GPs and also shown that through
close collaboration, effective communication is
improved. Pharmacists reported improved positivity
towards future inter-professional working. This study
also identified barriers to collaboration which require
further exploration. This was a small-scale study, thus
future studies evaluating GP and pharmacist collabora-
tive working using larger sample sizes should be con-
ducted. Study results should be utilised to inform future
studies to develop data collection tools exploring the
stages of collaborative working of HCPs.
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A worldwide view of collaboration
models involving community
pharmacists and general practitioners: a
systematic literature review
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Introduction: Collaborative patient-centred working
between healthcare professionals within the British
National Health Service (NHS) is one of its core strate-
gic values. The recently published NHS Long Term
Plan1 specifically encourages better integration of com-
munity pharmacists (CPs) within primary care teams
due to their skillset and regular engagement with
patients; this has come as a result of workforce short-
ages and financial pressures on general practitioners
(GPs) and urgent care. Whilst pharmacists are currently
being integrated into general practices as “practice-based
pharmacists”, insight is needed regarding optimising col-
laborative working between CPs and GPs. Thus, a sys-
tematic review (PROSPERO: CRD42018087846) was
undertaken.
Aim: To describe existing collaborative models in pri-
mary care that involve CPs and GPs in terms of their
drivers, purpose, impact on stakeholders (CPs, GPs and
patients) and evaluation, and to explore the extent to
which existing models align with seven published con-
ceptual models.
Methods: Full papers were included of primary empiri-
cal research on collaborative working that involved CPs
and GPs. Standard systematic review methods were
adopted2. Electronic databases were searched including:
Embase, MEDLINE, CINAHL Complete, Web of
Science Core Collection (on 14–15/03/2018; no restric-
tions were applied, e.g. language). Included studies’ ref-
erence lists were screened for additional references.
Validated risk-of-bias tools were used where appropri-
ate; when that was not possible, risk of bias was pre-
sented using a narrative summary. Identified models
were aligned to conceptual models with regard to model
characteristics (e.g. setting) and success determinants
(e.g. clear responsibilities for each collaborator
involved).
Results: Following 19,036 database hits (up to 15/03/
2018), data limitation was applied for the period 01/01/
2009 until 15/03/2018 generating 1,955 hits. In total, 43
papers (37 studies) were included in a narrative synthesis
(Figure 1). The included studies were quantitative (29/
43), qualitative (7/43) or mixed methods (7/43). Whilst
many studies investigated existing collaborations, many
involved the research teams in a key role as initiators/
coordinators of the service (33/43). Included papers
mainly focused on evaluating collaborative services (29/
43) rather than specifically exploring a model’s charac-
teristics and how they influenced its performance (2/43
and 11/43, respectively). CPs’ effectiveness as team
members varied in terms of clinical, process and finan-
cial outcomes. The identified models were categorised
into five main groups. The most common factors of suc-
cessful models included the CP collecting patient infor-
mation, discussion with healthcare professional(s) to
produce a care plan/report (with/without patient
involvement), and patient follow-up by the CP/GP.
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Analysis of the identified models’ purpose, drivers, CPs’
location, clarity on responsibilities and communication
reflected characteristics of the seven existing conceptual
models.
Conclusions: This review identified key features of CP-
GP collaborations worldwide. A limitation of this
review was that despite standardised data extraction,
not all studies presented every element in each model,
which was outlined in the research objectives (e.g. dri-
vers). Further research on current collaborative working
between CPs and GPs in primary care is required to
provide evidence-based recommendations for daily prac-
tice and policy on improving the flow of primary care
services through successful CP-GP collaborations, while
maintaining pharmacy resources within the community.
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Patient Safety
Using patient-held information about
medicines to enhance patient safety: a
mixed methods study
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Introduction: Poor transfer of information about medici-
nes across healthcare settings has been identified as a
major cause of medication errors.1 Many patients who
take medication carry patient-held information about
medicines (‘PHIMed’). However, it is not known how
PHIMed is used to improve patient safety, nor what its
key features are.
Aim: To identify how PHIMed is used to support
patient safety, key features that support this, and barri-
ers and facilitators to its use.
Figure 1. Adapted PRISMA flowchart2
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Methods: We used a mixed-methods design comprising
two focus groups with patients and carers, 16 semi-struc-
tured interviews with healthcare professionals, 60 semi-
structured interviews with PHIMed users, a quantitative
features analysis of PHIMed solutions available in the
UK, and usability testing of four PHIMed tools. We used
purposive sampling to recruit participants through our
personal and professional networks, a clinical research
network and support groups. We searched the literature,
app stores and data collected from participants to identify
PHIMed solutions available in the UK. Findings were tri-
angulated using thematic analysis, with Distributed Cog-
nition for Teamwork (DiCoT) models2 used as sensitising
concepts. Lay members of our advisory group con-
tributed to data analysis alongside researchers.
Results: We identified a wide range of mechanisms
through which PHIMed improved patient safety. These
included: creating connectivity between disjointed care
settings, enhancing situation awareness (‘Hang on, I am
on this as well. Is it ok to be on [them] together?’),
enabling patients to check they were being given the cor-
rect medication, ease of communication during consulta-
tions, acting as an aide-memoire for patients during
appointments, empowering patients to understand more
about their own medicines, reminding the patient to
take their medicines, and reminders to reorder. Different
PHIMed tools met different needs. However, of 103
tools examined (61 digital, 42 paper-based), none met
the core needs of all users that had been identified from
the data. A key barrier to PHIMed use was lack of
patient and carer awareness that healthcare information
systems can be fragmented, which meant that they had
not identified a need for PHIMed (‘I always assumed
the hospitals would know [what medicines I was tak-
ing]’). PHIMed use was facilitated by encouragement
from healthcare professionals.
Conclusions: This is the first in-depth study of a wide
range of PHIMed solutions. We considered contextual
factors relating to the use of PHIMed as well as the tools
themselves. Other strengths of the study are our relatively
large and varied sample for qualitative work, our mixed
methods design and our strong patient and public
involvement. The study was limited to one geographical
area at one point in time. However, the main findings are
likely to be relevant across settings. Our findings suggest
that PHIMed can contribute to the reduction of medica-
tion-related risk. Interventions are needed to raise aware-
ness of the role of PHIMed in enhancing patient safety.
Such interventions should empower patients to identify a
method that suits them best from a range of options,
avoiding a ‘one size fits all’ approach.
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A qualitative exploration of the
strengths and weaknesses of Jordan’s
pharmacovigilance system
H. Garashi, D. Steinke and E. Schafheutle
University of Manchester, Manchester, UK
Introduction: Pharmacovigilance (PV) plays a vital role
in ensuring medicines’ safety. Although PV is generally
well established in developed nations, it remains largely
underdeveloped in the Arab World. In an initiative to
unify PV practice across the Arab World, the ‘guideline
on good PV practices (GPVP) for Arab countries’ was
created by the League of Arab States’ Higher Technical
Committee for Medicines1. Four years have since
passed, yet little is known about how countries in the
region have implemented the guideline. A better under-
standing of the strengths and weaknesses of the more
developed systems within the Arab World will improve
policy development and implementation in lesser devel-
oped ones.
Aim: As part of a wider programme to inform the
implementation of the GPVP for Arab countries in
Arab countries with nascent pharmacovigilance systems;
this study aimed to identify the main strengths and
weaknesses of the PV system in Jordan, an Arab coun-
try which has a well-established national PV centre
(NPVC) as part of its drug regulatory authority.
Methods: Semi-structured face-to-face interviews were
conducted with individuals involved in the implemen-
tation of the PV policy in the Jordan Food and
Drug Administration (JFDA), regional PV centres,
and pharmaceutical companies operating in the coun-
try. Following JFDA and university ethics committee
approval, purposive and snowball sampling was used
to recruit eligible participants, who were emailed
study details via a gatekeeper at the JFDA. Inter-
views were audio-recorded with written consent, tran-
scribed verbatim, and analysed using thematic
framework analysis.
Results: Sixteen participants were interviewed: five from
the JFDA, two from regional PV centres, and nine from
pharmaceutical companies. The major perceived
strengths of Jordan’s PV system can be grouped into
three main themes: 1) the NPVC, (2) the country’s PV
policy and guideline, and (3) other general factors. In
terms of the NPVC, this included its early establishment
and membership in the WHO Programme for Interna-
tional Drug Monitoring (PIDM). Regarding the coun-
try’s PV policy, examples were its use of the Arab and
EU GPVP guidelines as a basis, feasibility in terms of
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implementation, and domestic focus. With respect to
other general factors, these included the presence of
regional PV centres covering the entire country as well
as increasing awareness levels amongst reporters regard-
ing PV. The perceived weaknesses centred on five
themes: (i) reporting-related issues, (ii) lack of resources,
(iii) NPVC deficiencies, (iv) regional PV centres’ issues,
and (v) pharmaceutical companies-related issues. One
example of reporting-related issues was under-reporting.
Lack of resources included both human and financial.
NPVC deficiencies included its lack of independence
from the JFDA, and its staff’s lack of continuous train-
ing. Examples of regional PV centres’ issues were lack
of interconnectivity and autonomy. Finally, with respect
to pharmaceutical company-related issues, these
included the absence of a dedicated PV department and
personnel.
Conclusions: This study offers detailed insights into the
strengths and weaknesses of Jordan’s PV system, which
will provide valuable insights for other Arab countries
with nascent PV systems to design or improve their PV
systems. Future work will involve exploring the
strengths and weaknesses in two other Arab countries
with less well-developed PV systems than Jordan’s in
order to compare and contrast the differences between
the three countries. This will facilitate making recom-
mendations for the development of a more robust PV
system in Arab World countries with nascent PV sys-
tems.
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Defining a medicines related serious
incident – an E-Delphi study
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Introduction: Serious Incidents (SIs), are defined as
adverse events which causes considerable harm to
patients, families, carers and staff, include never events,
and/or events that have a negative impact on the reputa-
tion and ability of an organisation to deliver effective and
quality healthcare service. Government requires a detailed
investigation to be undertaken of all SIs occurring within
the National Health Service (NHS) and hold organisa-
tions accountable for implementing actions to address
identified concerns. Between 2017/18, approximately 2660
medication safety incidents were reported by NHS Wales
to the UK National Reporting and Learning System1.
Based on the SI definition and extrapolation of patient
harm data, approximately 110 medicines related SI
reports were anticipated that year. However, only three
medication-related SIs were reported during the year.
This under-reporting may be attributed to a poor under-
standing of the SI definition and lack of explicit guidance
on medication incidents constituting a SI. This study
aimed to develop a practitioner-led consensus definition
of a medicines related SI to inform policy and practice.
Method: Consensus was determined through use of a
three-staged electronic-Delphi technique. An anonymous
survey was distributed by e-mail to an international panel
of 107 practitioners (physicians, surgeons, pharmacists,
nurses and risk managers). Participants were asked to rate
the extent to which they agreed with the general definition
of a SI and 30 clinical scenarios representing a medicine-
related SI. Clinical scenarios encompassed a range of
medication incident types (e.g. prescribing, dispensing,
preparation, administration and monitoring errors), dif-
ferent medication, level of patient harm and preventabil-
ity. Participants were asked to rate agreement on a 5-
point Likert scale from strongly disagree to strongly
agree. Consensus was defined as 80% agreement.
Results: Responses were obtained from 22% (23/107),
70% (16/23) and 69% (11/16) of respondents in each
round respectively. Consensus was achieved for the cur-
rent SI definition. The panel were in agreements that the
SI definition should also include: adverse events with the
potential to cause permanent harm or death; involve
deliberate harm; result in reproductive toxicity; involve
medicines subject to a Government patient safety alert/
notice; are attributable to a medical device; result in over-
dose of a prescribed/unprescribed medication (regardless
of the medication involved); administration to the incor-
rect patient; involve lack or inappropriate monitoring of
medication and the prescribing and/or administration of
a medication to which the patient has a known allergy.
Discussion: Despite the low response rate to the initial
survey, the general SI definition was considered applica-
ble to medicines related SIs by international experts.
However, an expanded list of incident types that consti-
tute a medicine-related SI was developed. It is proposed
that use of this revised and explicit definition of a medi-
cine-related SI would facilitate reporting and learning
from medication incidents at an organisational and
national level, thereby safeguarding patient safety and
ensuring excellence in clinical care. However, the appli-
cation of the definition in practice was not evaluated.
Further work is needed to validate and test the defini-
tion for user acceptability through application to real-
life situations occurring in clinical practice.
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Adverse drug reactions in UK primary
care consultations: a retrospective
cohort study to evaluate impact on
appointments and treatment
discontinuation
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Introduction: Adverse drug reactions (ADRs) are
directly cause morbidity, hospitalization and mortality.
Patient concerns about ADRs are associated with treat-
ment non-adherence and escalation and healthcare seek-
ing, further increasing the burden of illness on patients.
Pharmacists have a key role in informing patients about
adverse effects and supporting them to make decisions
about treatment. No study has explored the overall bur-
den of ADRs in UK general practice.
Aim: To quantify the prevalence of ADR-related con-
sultations in UK primary care and impact on primary
care appointments and treatment discontinuation.
Methods: We conducted a retrospective cohort study
using routinely collected data from UK primary care
practices participating in the Clinical Practice Research
Datalink (CPRD). As per CPRD procedures, Indepen-
dent Scientific Advisory Committee approval was sought
prior to accessing anonymised patient-level data Patients
prescribed at least one medication who discussed an
ADR in a consultation in 2014 were identified and they
were followed up until the end of 2015. We compared
their rates of subsequent consultations and treatment
discontinuation in 2015 to those of matched controls
(by age, gender, practice and whether they had a GP
consultation within 3 months of the case’s ADR-related
consultation) who had no ADR-related consultation
using zero-inflated Poisson regression. We calculated the
incidence rate ratios (IRR) and the 95% confidence
intervals to compare consultation rates between the
ADR and control groups.
Results: In 2014, 96,865 patients, equivalent to 3% of
all patients had at least one ADR-related consultation.
Of these, 96,087 were matched to 190,977 controls (up
to 2 controls per case) who had no ADR-related consul-
tation. Women were more likely to have an ADR-
related consultation than men (65% vs 35%). There was
a 33.1% increase in consultation rate for 2015 (IRR
1.331, 95% CI 1.329 to 1.333) in the ADR group com-
pared with the control group with a median number of
consultations per patient of 33 (interquartile range
(IQR), 19–52) in the ADR group and 20 (IQR, 11–34)
in the control group. Treatment discontinuation in 2015
was higher in patients with an ADR-related consultation
in 2014, than patients without an ADR-related consulta-
tion. For example, 10.1% patients with an ADR-related
consultation in 2014 discontinued aspirin in the follow-
ing year, whereas only 6.5% of controls did so.
Conclusion: ADRs place a significant burden on UK
primary care and UK patients, with 3% of patients hav-
ing ADR-related consultations, equivalent to approxi-
mately 1.57 million people per year. These patients
subsequently have increased rates of treatment discon-
tinuation and consultations in primary care, suggesting
that they may have poorer disease management or
unmet needs. This study has limitations including: 1)
many ADRs may not be discussed by patients with pri-
mary care providers or recorded in the CPRD meaning
that these findings will not represent the full picture of
ADRs in UK primary care; 2) we only took a ‘snap-
shot’ of follow-up consultations and discontinuation in
2015 and so it is likely that additional discontinuations
and consultations may have occurred, and 3) it is not
possible to draw a causal link between ADR-related
consultations and these outcomes. However, our results
highlight that there may be missed opportunities to
reduce healthcare utilization, patient morbidity and
treatment discontinuation during ADR-related consulta-
tions in UK primary care. It is not known whether the
recent focus on practice-based pharmacists will address
this need.
Undergraduate Education
Does an early longitudinal community
practice placement for pharmacy
students promote learning by
establishing more opportunities for
connection with patients, curriculum
integration and professional
engagement? A Mixed Methods Study
A. Kerr, T. Pawlikowska, F. Boland and
J. Strawbridge
RCSI, Dublin, Ireland
Introduction: Longitudinal clinical placements are
defined as involving “a regular, recurrent placement in
the same setting with the same supervisor over a period
of time”. The underlying mechanism promoting learning
is “continuity” in its varying forms of patient, supervi-
sor and longitudinal exposure. Longitudinal placements
have been reported to promote learning by establishing
more opportunities for connection with patients
(“continuity of care”), integrating knowledge, skills and
attitudes across science and practice (“continuity of cur-
riculum”) and enhancing supervision, role modelling
and mentoring (“continuity of supervision”)1. The longi-
tudinal community pharmacy placement (LCPP) in the
institution was designed for second year students to
attend the same community pharmacy site for a half
day each week for 12 weeks.
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Aim: This study sought to answer the question: Does an
early longitudinal community practice placement for
pharmacy students promote learning by establishing
more opportunities for connection with patients, cur-
riculum integration and professional engagement?
Methods: This was an explanatory mixed methods
study. Data for the quantitative before and after study
were collected using a validated tool called the Student
Pharmacist Inventory of Professional Engagement (S-
PIPE)2 and the questionnaire, also contained questions
related to connection with patients and curriculum inte-
gration. Qualitative semi-structured interviews, focussed
on continuity of care, curriculum and supervision, with
students, supervisors and practice-educators were con-
ducted following the 12-week longitudinal placement.
The interviews focused on continuity of care, curriculum
and supervision and were thematically analysed.
Results: 78% (n = 47/60) students completed the ques-
tionnaire. Significant increases in the sum scores for pro-
fessional engagement (S-PIPE) and sub-scores for
belonging, meaningful experience and connectedness
were recorded post-placement. Some increases were
recorded relating to connection with patients. The
majority of students agreed that the placement helped
them to contextualise and apply knowledge learned
from modules. 13 students and 12 pharmacists were
interviewed. Most participants described the placement
supporting curriculum integration, considering the sug-
gested learning activities very useful to promote integra-
tion of module content and practice. Continuity of care
was not as widely discussed as some pharmacists had
seen this as more of an observational placements and
students saying they did not get the chance to speak to
patients. However, some pharmacists allowed their stu-
dents to serve customers and practice patient coun-
selling, which from a student lens was very useful,
particularly when they built relationships with patients
they saw recurrently. Pharmacists and students felt that
the longitudinal nature of the placement promoted
building a professional working relationship over time.
However, some pharmacists were not there on a number
of student placement days, limiting the opportunity to
build a relationship and students felt that days where
locums were working were less beneficial.
Conclusions: The LCPP promotes professional engage-
ment through role modelling, professional working rela-
tionships and repeated supervisor interactions.
Curriculum integration is promoted through learning
activities, and the longitudinal nature of the placement
allowed for opportunities to link to modules being stud-
ied at the same time and for linking to more modules.
Patient-centred beliefs are promoted but issues including
not seeing interaction to completion and inconsistences
in level of interaction with patients, depending on place-
ment. Possible issues to be addressed include reviewing
the 3 hours’ duration of the day and more guidance on
the expected level of interaction with patients.
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Pharmacy Longitudinal Clerkship (PLC):
a pilot placement developing MPharm
students’ clinical skills for patient-
centred care through general practice
integration in remote and rural settings
C. Innes1,2, G. Rushworth2, A. Brown1, B.
Addison1, Y. Wedekind3, I. Rudd4,
A. Power5 and S. Cunningham1
1Robert Gordon University, Aberdeen, UK 2HPERC, NHS Highland,
Inverness, UK 3HMEC – NHS Highland, Inverness, UK 4NHS Highland,
Inverness, UK and 5NHS Education Scotland, Glasgow, UK
Introduction: Research in older people in remote and
rural (R&R) areas shows a lack of access to pharmacy
services1 but pharmacists offer value in R&R General
Practices.2 Undergraduate R&R Longitudinal Integrated
Clerkships exist in medicine courses and a pilot R&R
Pharmacy Longitudinal Clerkship (PLC) was supported
by the Scottish Government and NHS Education for
Scotland to enhance student clinical skills for patient-
centred care (PCC) and help recruitment issues. Enhanc-
ing PCC through experiential learning and clinical skills
development supports a 5 Year integrated MPharm.
Aim: To identify, characterise and quantify the structures
and processes for a PLC and explore the outcomes arising
including the views and experiences of all participants.
Method: The 11-week PLC was based in GP practices in
the NHS Highland Board area. Mixed methods were used
for data generation. Information on structures and pro-
cesses was systematically gathered throughout the project.
The outcomes were explored through qualitative methods
using semi-structured interviews with participating stu-
dents and GP tutors. Informed written consent was
obtained from all participants. An interview schedule was
developed and piloted using the Theoretical Domains
Framework (TDF). Interviews were audio-recorded, tran-
scribed verbatim and analysed using thematic analysis.
Results: Structures (resources) and processes required for
a PLC were identified and included; overarching learning
outcomes, training timetable induction and support tuto-
rials, quantification of funding required for student travel
and accommodation and GP Practice contracts and
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payment, requirements for and cost of clinical equipment
‘Kit Bag’ for each student, robust processes for student
recruitment, liaison and communication with GP prac-
tices, and student attendance monitoring and support.
Interviews evaluating outcomes have been carried out
with 2 students that completed the pilot PLC to-date and
the 2 linked GP tutors. Emerging themes from students
include; greater understanding of PCC and application of
knowledge and skills: “I did use my knowledge quite a lot
and it does get you thinking ‘cause they’re real
patients”[SP1], “it’s totally different with a real life
patient”[SP2], increased confidence and optimism: “I feel
like I’ve just become more and more confident”[SP1], “I do
know that I can solve problems”[SP2], “I feel more pre-
pared for what’s coming”[SP2] and excitement for being a
pharmacist: “excited to start pre-reg and actually be a
pharmacist” [SP1]. For GP tutors, themes included Issues/
challenges/differences – supporting pharmacy v medical
students, positive experiences and personal development,
concerns and need for enhanced ‘clinical’ preparation.
Conclusion: The outcomes of this pilot, although limited
by number of participants and settings, were extremely
positive in terms of student and tutor experience and infor-
mation has been garnered on requirements for resources
and processes for future development. As a result, funding
has been secured to extend it for five students to five GP
practices each year for the next two years. Evaluation of
outcomes will continue; further work will include longitu-
dinal follow-up of students to determine the success of the
programme in enabling students to progress to advanced
level clinical practice in R&R settings.
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Pharmacy practice orientation: an
investigation of final year students’
career preferences
S. Willis1, P. Harsha1, J. Barry2,
V. Silkstone1 and S. Haughey2
1University of Manchester, Manchester, UK and 2Queens University,
Belfast, UK
Introduction: New models for pharmacy practice aim to
increase pharmacy’s contribution to patient outcomes. If
pharmacy graduates are to adopt the patient-focused,
clinical-service practice orientation underpinning these
models an understanding of how practice orientation is
shaped during undergraduate education is needed. While
experiential learning exposes students to practice, in the
context of limited curriculum opportunities, in this
study, we investigate the extent to which practice experi-
ence contributes to pharmacy students’ practice orienta-
tion and career preferences.
Aim: To identify final year pharmacy students’ Profes-
sional Practice Orientation (PPO), and the association
between this, practice experience, commitment to prac-
tice and career preferences.
Methods: Final year undergraduate pharmacy students
from five MPharm programmes (n = 465) were invited
to complete a survey capturing number of placements
completed in hospital and community pharmacy dur-
ing each year of their MPharm, career preference,
commitment to practice, and Professional Practice Ori-
entation (PPO). PPO was measured using an adapted
validated tool assessing pharmacy service orientation1.
In our study PPO was operationalised via three
dimensions: orientation (preference for clinical vs busi-
ness career); focus (patient vs medicine career prefer-
ence) and future career pathway (alternative vs
traditional career preference). Variation in PPO, calcu-
lated as the mean of the three scales, was investigated
using t-tests and ANOVA; a lower PPO score indi-
cated preference for a clinical rather than business
career, a focus on the patient compared with the med-
icine, and an alternative career pathway compared
with a traditional one; correlation between PPO and
total number of MPharm practice placements was also
investigated.
Results: Three hundred and fifty-two students com-
pleted the survey (75.7% response rate). Most students
(n = 351; 99.4%) had at least one placement in both
community and hospital pharmacy organised by their
programme and many also self-organised a placement
in hospital (n = 118) and community pharmacy
(n = 240). Mean number of placements in community
and hospital pharmacy varied significantly between the
programmes (P < 0.001) (range 8–16 for both commu-
nity and pharmacy placements). Mean PPO score was
12.36; no correlation with total community or phar-
macy placements was found (P > 0.05), suggesting
placements had not influenced respondents’ practice
orientation. Students with a preference for a commu-
nity pharmacy career scored significantly higher than
those with a preference for hospital pharmacy, indicat-
ing a practice orientation towards business, focused
more on medicines than patients and following a tra-
ditional career pathway amongst this subgroup (mean
13.54 vs 10.95; P < 0.001); those strongly committed
to practising pharmacy scored significantly lower than
those whose commitment was weak (mean 11.93 vs.
13.37; P = 0.002).
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Conclusion: While limited by the use of an adapted
tool for measuring pharmacy practice orientation and
lack of data capturing duration or content of practice
experience, findings provide some insight into final
year students’ career preferences and orientation
towards future practice. Noticeably, while new models
for practice are organised around a concept of the
patient as the ‘social object’ of pharmacy, respondents
preferring a career in community pharmacy were more
likely to have been orientated towards medicines and
on business priorities, despite policy-makers’ emphasis
on the need for this sector to increasingly provide
patient-centred, clinical services.
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An evaluation of pharmacy student use
and perceptions of lecture-capture
podcasting
J. Silverthorne, J. Ouyang and Y.Y. Chow
University of Manchester, Manchester, UK
Introduction: Blended learning is used by pharmacy
schools in the UK, where didactic teaching is used
alongside novel methods such as simulation. As students
are frequently familiar with newer technology, many
universities have also implemented lecture-capture pod-
casting (live video recording of slides with audio of lec-
turer narrative) as a tool to supplement learning.
Emerging research suggests that it is popular1 and that
pharmacy students are well engaged2. A key advantage
of podcasts is that they can be accessed at any time and
played multiple times. However, there is mixed opinion
on whether podcasting decreases engagement with lec-
tures and its effect on academic performance. There is
therefore a need to better understand how students use
podcasts and their perceptions of them.
Aim: To investigate how pharmacy undergraduates
engage with lecture capture podcasts to facilitate their
learning and their perceptions of their usefulness.
Methods: A questionnaire was distributed to all phar-
macy undergraduates at a university in the north of
England. An information sheet was emailed a week
before, with the questionnaire distributed during com-
pulsory classes over a one-week period. Participants
gave their consent by ticking a box on the front of the
questionnaire. Questions explored frequency of access,
how and when podcasts were used and perceptions on
usefulness. A combination of closed questions to explore
podcast use, and 10-point rating scales and free text
comments to capture student perceptions were used.
Data from completed questionnaires were entered onto
Microsoft Excel; simple descriptive statistics were used
to analyse the numerical data and a thematic analysis
performed on comments provided.
Results: There were 441 questionnaires completed (re-
sponse rate of 73%). Analysis of quantitative data
revealed that the majority of students (249, 56.5%)
watched full podcasts on a single occasion with fewer
skipping to specific parts for a single clarification (74,
16.9%). Notably, reported podcast use was greater
across all year groups for modules assessed by examina-
tion with access predominantly in the week following
the lecture and before examinations. Analysis of respon-
dent comments identified two themes around lecture
attendance and study habits; podcasts helped students
catch up on missed lectures and allowed them to revisit
difficult content. However, some comments revealed
behaviours of concern to educators; the need to capture
lectures verbatim and justification to not attend lectures:
“.. allows you to write up everything the lecturer says
enabling you to never miss a single detail”. “I mostly
don’t come to lectures because I know that I can access it
via podcasts.”
Conclusion: This study achieved a good response rate
and provided further insight into the varied ways in
which undergraduates engage with podcasts. The study
was limited to one university and so findings may not
be generalisable, and student responses were not
linked with assessment marks to explore effects on
performance. The study was further limited by a lack
of subgroup analysis (e.g. mature students), due to
insufficient respondents. There is still scant evidence
on the educational advantages of podcasts and how
students should use them in order to improve assess-
ment performance, which are important areas for
future research.
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Users’ and Caregivers’ Views
Caregivers’ perspectives of pain
assessment and management in people
with advanced and end-stage dementia:
a qualitative analysis of an online
discussion forum
C. Parsons and K. Clarke
Queen’s University Belfast, Belfast, UK
Introduction: Pain assessment and management in
advanced and end-stage dementia are challenging; in
these stages of dementia, people are often unable to
effectively communicate their pain, which increases the
risk of under-assessment and under-treatment of pain in
this vulnerable patient population1. Little is known
about the experiences of informal caregivers (family
members, friends) of people with advanced and end-
stage dementia with regard to pain assessment and man-
agement.
Aim: The aim of this study was to investigate the expe-
riences of informal caregivers of people with advanced
and end-stage dementia with respect to pain assessment
and management. Study objectives were to systemati-
cally search the discussion threads and posts of the
online Talking Point discussion forum, hosted by the
Alzheimer’s Society for anyone affected by dementia, to
explore the experiences of caregivers and family mem-
bers of people with advanced dementia in assessment
and management of pain nearing the end of life.
Method: Qualitative analysis of archived discussion
threads and posts of the Talking Point online forum.
All threads between 2005 and January 2019 were
searched using combinations of the following search
terms: ‘pain’, ‘pain assessment’, ‘pain management’, ‘de-
mentia’, ‘advanced dementia’, ‘severe dementia’, ‘pain
relief’, analgesia’, ‘end of life’, ‘morphine’, ‘fentanyl’,
‘syringe driver’, ‘paracetamol’, ‘codeine’, ‘diamorphine’,
‘buprenorphine’, ‘patch’, ‘oxycodone’. Brand names
were searched: ‘Oxynorm’, ‘Oxycontin’, ‘MST’, ‘Sevre-
dol’, ‘Mezolar’, ‘Butec’, ‘Butrans’. Relevant threads were
analysed thematically. The School of Pharmacy Ethics
Committee granted ethical approval for the study and
the Alzheimer’s Society granted permission for use of
archived discussions from the Talking Point website.
Results: The search yielded 118 posts made by 79 users
within 53 threads, which spanned the full period of
forum activity. Seven key themes emerged from data
analysis: (1) the importance of being comfortable, pain
free and dignified; (2) inadequate/inappropriate assess-
ment and management of pain; (3) healthcare profes-
sional/family fears over ‘strong’ pain relief; (4) fighting
or advocating for pain relief; (5) timely access to pain
relief; (6) interactions/communication with healthcare
professionals and other family members; and (7) emo-
tional burden and impact on caregivers.
Conclusion: This is the first study to provide an insight
into caregivers’ experiences and perspectives of assess-
ment and management of pain in end-stage dementia. It
highlights the complexity and the difficulties encoun-
tered by caregivers in achieving adequate pain assess-
ment and management in this vulnerable patient
population. Further research into how expectations of
caregivers can be met to ensure a comfortable, pain-free
death is warranted. The strength of this study lies in the
analysis of posts from an online discussion forum, which
represents a large data source. Talking Point users were
anonymous and the forum can be considered to be a
large naturally occurring focus group; the risk of social
desirability bias was therefore minimized. Limitations
must be considered in interpreting the study findings;
one website was analysed therefore generalizability or
transferability to a wider population cannot be assumed.
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A qualitative study exploring service
users’ experiences of NHS patient
medicines helpline services
M. Williams, A. Jordan, J. Scott and M. Jones
University of Bath, Bath, UK
Introduction: Patient medicines helpline services (PMHS)
have been set up at some National Health Service
(NHS) Trusts in the UK, with the aim of providing a
medicines information service to recently discharged
hospital patients and their carers. Seeking to understand
the experiences of service users may result in improved
healthcare services, and a recent systematic review high-
lighted that, to date, studies of PMHS have predomi-
nantly examined the views of service users using user
satisfaction surveys1. However, survey studies have limi-
tations, such as not enabling participants to provide
information that is important to them, nor allowing par-
ticipants to respond using their own words. Surveys are
therefore not well suited to explore why and in what
ways services are useful, nor how they could be
improved. In order to achieve this, qualitative methods
would be more appropriate.
Aim: In order to explore the benefits and potential limi-
tations of PMHS, and thus develop recommendations
for service improvement, the following research question
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was to be addressed: What are patients’ and carers’
experiences of using an NHS PMHS?
Methods: Recruitment was conducted via seven NHS
Trusts in England (four acute Trusts, one mental health
Trust, one specialist Trust, and one community Trust).
Invitations to participate were sent from Trusts to help-
line enquirers who agreed to receive study information.
Interested individuals contacted the research team to par-
ticipate. Study materials (interview schedule, study infor-
mation sheet) were reviewed by seven members of the
public (recent patients and carers) prior to their use. The
interview schedule primarily focused upon the enquiry
reason, perceived helpfulness of the service, perceived
ways to improve the service, perceived impact of the use
of the service, and what would have been done had the
PMHS not existed. Semi-structured interviews were con-
ducted via telephone. Interviews were audio-recorded and
transcribed verbatim. Transcripts were imported to
NVivo (version 12) and analysed using thematic analysis2.
Results: Forty service users participated in this study
(patients = 33%, carers = 18%; female = 58%,
male = 42%; White or White British = 95%, predomi-
nantly having used a PMHS from an acute NHS Trust,
95%). Two themes were generated from the analysis:
Timeliness, and Best-placed to help. The findings illus-
trate how PMHS provide support during the uncertain
transition of care period, when patients and carers often
feel vulnerable because support is less available. Partici-
pants described how PMHS met their need for timely
and easily accessible support and quick resolution of
their queries. However, there was recognition that
PMHS could be improved by being available during
evenings and weekends, and also by increasing their pro-
motion. PMHS were perceived as being best-placed to
help to answer enquiries that arose from hospital care.
Participants described feeling reassured from speaking
to pharmacy professionals, and PMHS were perceived
as the optimal service in terms of knowledge and exper-
tise regarding questions about medicines.
Conclusions: This study highlights that PMHS are seen
as a valuable means of accessing timely medicines-related
support at a time when patients and carers may be feel-
ing particularly vulnerable. However, PMHS could be
improved by being available during evenings and week-
ends, and by increasing their promotion. We recommend
that providers of PMHS consider whether this is achiev-
able, in order to better meet the needs of service users.
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Perceptions of migraine and experiences
of its management: a qualitative study
using theoretical framework analysis
R. Evans and D. James
Cardiff Metropolitan University, Cardiff, UK
Introduction: Migraines can have negative effects on
many areas of a person’s quality of life, such as social,
work and family life. The physical impact on the indi-
vidual can also result in negative feelings, such as
depression. Migraine sufferers develop different coping
strategies to manage their condition, which often include
both pharmacological and non-pharmacological treat-
ment. It is important that pharmacy professionals have
a good understanding of how patients make decisions
about what migraine treatments to take and when, in
order to play an effective role in helping to manage their
condition. A number of health psychology theories have
been developed to understand human behaviour in
response to illness, such as Leventhal’s Common Sense
– Self-Regulatory Model (CS-SRM)1.
Aim: To explore individuals’ experiences and percep-
tions of migraines and their treatment.
Methods: A qualitative methodology was adopted using
one-to-one semi-structured interviews. An interview sched-
ule was designed based on the five components of the CS-
SRM1 applied to migraines to capture perceptions of iden-
tity, cause, time-line, cure-control and consequences. Other
open-ended questions related to experiences of migraines
and its management. Inclusion criteria were individuals
over 18 years whom had experienced at least one migraine
in the last six months. Participants were recruited via snow-
ball-sampling, starting with an email invitation to individu-
als known to the research team. Interviews were audio-
recorded, transcribed verbatim and theoretical framework
analysis was conducted, followed by thematic analysis for
data that did not map onto the theory2.
Results: Of the eleven participants interviewed, nine
were females and ages ranged from 20 to 59 years. Nine
were educated to degree level or above and five had a
background in healthcare disciplines. Four overarching
themes emerged from the data. Three themes mapped
directly on to the CS-SRM. These were: 1) Emotional
illness representations (two sub-themes a. Life-related
and b. Disease-specific); 2) Cognitive illness representa-
tions (five sub-themes a. Identity, b. Cause, c. Timeline,
d. Control/cure and e. Consequences); 3) Behaviour
(two sub-themes a. Seeking advice and b. Medicine-tak-
ing). One further overarching theme emerged from the
remaining data, 4) Attitude towards migraine (two sub-
themes a. Treatment-related and b. Disease-related).
Conclusion: Theoretical framework analysis was success-
fully employed in this small-scale study, since participants’
experiences and perceptions of migraines mapped on to all
elements of the psychological theory utilised, the CS-SRM.
The findings highlighted a number of different treatment-
related and disease-specific issues, which influenced the
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personal strategies adopted for managing migraines. Addi-
tionally, the emotional aspect of the condition was a strong
feature of the interviews. These are all important consider-
ations when consulting with patients who experience
migraines. The study had a number of limitations due to
the likelihood of sampling bias due to the method of
recruitment and small number of interviews. However,
these data provide a good basis for the next quantitative
phase of the research, to design a questionnaire to capture
the perceptions and experiences of a larger sample of
migraine sufferers from a more diverse population.
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Web-based video consultations: are they
acceptable to patients with Chronic
Myeloid Leukaemia (CML)?
T.W.T. Ng
UCL School of Pharmacy, London, UK
Introduction: In recent years there has been a rise in offer-
ing web-based video consultations in the NHS and private
healthcare. In 2015, the Independent Cancer Taskforce
recommended a review of “how digital technologies might
be used to drive improvements in patient experience”1 for
example by minimising the need for some patients to tra-
vel to appointments. CML is a chronic cancer and some
patients are stable on long term treatment. Providing clin-
ical tests were undertaken locally to their home, a video
consultation could save such patients travelling to a spe-
cialist centre. The VOCAL study2 is one of the few pub-
lished studies on video consultations with cancer patients,
using Skype to support a NHS hepato-pancreato-biliary
cancer service. This paper identified a need to analyse the
acceptability of this type of service.
Aim: To explore whether it would be acceptable to
CML patients at a NHS tertiary cancer centre to have
follow-up appointments using web-based video consulta-
tions and evaluate their experience.
Methods: A mixed methods study was undertaken using
semi-structured interviews, focus groups and a questionnaire.
Interviews were conducted with CML patients from the can-
cer centre, and focus groups with patients recruited across the
UK with the aim of comparing views and experiences of
patients across the wider CML population. Eligible interview
participants were identified using purposeful sampling. Focus
group participants were recruited through Bloodwise Ambas-
sadors, CML Support and support groups via Facebook.
The questionnaire was developed using questions from the
National Cancer Patient Experience Survey (NCPES) and
findings following a literature review, which also informed
the focus group and interview topic guides. Written consent
was received from patients before participation. The ques-
tionnaire was reviewed by a non-participating CML patient
and all participants completed a paper version as part of the
interview or focus group. Interviews and focus groups were
audio-recorded and transcribed verbatim before undergoing
thematic analysis.
Results: For two focus groups, n = 8 and interviews
n = 5, Table 1 shows the common themes. All partici-
pants (n = 13) completed the questionnaire. Questions
relating to education on side effects scored lower than the
national average. However, the question about involve-
ment in decisions about care and treatment, the focus
group participants scored this at 86% and interview par-
ticipants at 80% vs a national score of 77% in 2018.
Table 1. Common Qualitative Themes
Theme Participant Quote
Standards of
Care
“. . .they lost my blood five times. . ..”“the lab
should be certified, we need to be sure that
they will send it within time”
Continuity of
the team
“I would say the web based consultation,
whatever it is, if it chopped around from
different people all the time it really wouldn’t
be a good idea. . .”
Flexibility “I don’t think it has to be either or, I think
that’s of a hybrid, could probably work very
well.”
NHS Context “I think a web based consultation would be
perfectly acceptable, but only if the
efficiencies are generated. . .. . .”
Conclusion: The qualitative aspect of the study may
have limited the number of participants however, it
allowed for exploration in greater depth and themes to
emerge to inform future studies on video consultation
acceptability. The results suggest certain factors relating
to patient experience need to be considered before
launching such a service and acceptability varied
depending on the management of these factors. How-
ever, most participants would be accepting of such a ser-
vice if the NHS benefitted.
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